NanoViricides (NNVC) 10-K 14 Sep 15 2015 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Jun. 30, 2015	Sep. 14, 2015	Dec. 31, 2014
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Entity Registrant Name	NANOVIRICIDES, INC.
Entity Central Index Key	1,379,006
Current Fiscal Year End Date	--06-30
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float			$ 112,046,000
Trading Symbol	NNVC
Entity Common Stock, Shares Outstanding		57,240,000

Balance Sheets

Balance Sheets - USD ($)	Jun. 30, 2015	Jun. 30, 2014
CURRENT ASSETS:
Cash and cash equivalents	$ 31,467,748	$ 36,696,892
Prepaid expenses	214,425	108,089
Other current assets	0	150,000
Total Current Assets	31,682,173	36,954,981
PROPERTY AND EQUIPMENT
Property and equipment	13,496,851	6,736,742
Accumulated depreciation	(1,534,203)	(1,239,986)
Property and equipment, net	11,962,648	5,496,756
TRADEMARK and PATENTS
Trademark and patents	458,954	458,954
Accumulated amortization	(59,217)	(50,696)
Trademark and patents, net	399,737	408,258
OTHER ASSETS
Security deposits	0	1,000,000
Service agreements	142,531	0
Other Assets	142,531	1,000,000
Total Assets	44,187,089	43,859,995
CURRENT LIABILITIES:
Accounts payable	89,517	376,446
Accounts payable - related parties	316,196	49,455
Accrued expenses	28,515	91,838
Deferred interest payable - current portion	166,667	0
Total Current Liabilities	600,895	517,739
LONG TERM LIABILITIES:
Debenture subscription deposit	0	5,000,000
Deferred interest payable - long term portion	333,333	0
Total Long Term Liabilities	11,800,327	19,972,953
Total Liabilities	$ 12,401,222	$ 20,490,692
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY:
Common stock, $0.001 par value; 150,000,000 and 85,714,286 shares authorized, respectively, 57,242,070, and 54,620,993 shares issued and outstanding, respectively	$ 57,242	$ 54,621
Additional paid-in capital	85,824,613	75,212,888
Accumulated deficit	(54,099,572)	(51,901,400)
Total Stockholders' Equity	31,785,867	23,369,303
Total Liabilities and Stockholders' Equity	44,187,089	43,859,995
Warrant [Member]
LONG TERM LIABILITIES:
Derivative liability	3,442,754	5,235,682
Series B Debentures [Member]
LONG TERM LIABILITIES:
Debenture subscription deposit	4,700,582	4,037,568
Derivative liability	366,764	5,699,703
Series C Debentures [Member]
LONG TERM LIABILITIES:
Debenture subscription deposit	2,480,605	0
Derivative liability	476,289	0
Series A Convertible Preferred Stock [Member]
STOCKHOLDERS' EQUITY:
Preferred stock	3,584	3,194
Series B Convertible Preferred Stock [Member]
STOCKHOLDERS' EQUITY:
Preferred stock	0	0
Series C Convertible Preferred Stock [Member]
STOCKHOLDERS' EQUITY:
Preferred stock	$ 0	$ 0

Balance Sheets _Parenthetical_

Balance Sheets [Parenthetical] - $ / shares	Jun. 30, 2015	Jun. 30, 2014
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	150,000,000	85,714,286
Common stock, shares issued	57,242,070	54,620,993
Common stock, shares, outstanding	57,242,070	54,620,993
Series A Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	4,000,000
Preferred stock, shares issued	3,583,445	3,193,079
Preferred stock, shares outstanding	3,583,445	3,193,079
Series B Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series C Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
OPERATING EXPENSES
Research and development	$ 3,660,322	$ 5,131,523	$ 4,292,909
General and administrative	3,402,778	3,535,849	2,297,470
Total operating expenses	7,063,100	8,667,372	6,590,379
LOSS FROM OPERATIONS	(7,063,100)	(8,667,372)	(6,590,379)
OTHER INCOME (EXPENSE):
Interest income	160,859	171,001	55,587
Interest expense	(2,649,592)	(3,092,550)	(962,535)
Discount on convertible debentures	(1,175,344)	(569,495)	(129,006)
Change in fair value of derivatives	8,529,005	(1,443,200)	(1,249,335)
Other income (expense), net	4,864,928	(4,934,244)	(2,285,289)
LOSS BEFORE INCOME TAXES	(2,198,172)	(13,601,616)	(8,875,668)
INCOME TAX PROVISION	0	0	0
NET LOSS	$ (2,198,172)	$ (13,601,616)	$ (8,875,668)
NET LOSS PER COMMON SHARE
Basic (in dollars per share)	$ (0.04)	$ (0.27)	$ (0.19)
Diluted (in dollars per share)	$ (0.09)	$ (0.27)	$ (0.19)
Weighted average common shares outstanding
Basic (in shares)	56,553,848	51,225,622	45,892,549
Diluted (in shares)	59,220,515	51,225,622	47,606,835

Statement of Changes in Stockho

Statement of Changes in Stockholders' Equity - USD ($)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Series A Preferred Stock [Member]	Series C Preferred Stock [Member]
Balance at Jun. 30, 2012	$ 13,850,192	$ 44,460	$ 43,227,028	$ (29,424,116)	$ 2,820	$ 1
Balance (in shares) at Jun. 30, 2012		44,460,629			2,820,357	672
Series A Preferred Shares issued for employee stock compensation	445,044		444,874		$ 170
Series A Preferred Shares issued for employee stock compensation (in shares)					169,643
Series C Preferred Shares issued to SeaSide 88	2,541,872		2,541,872
Series C Preferred Shares issued to SeaSide 88 (in shares)						714
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88	(1)		(1)			$ (1)
Retirement of Series C Preferred Shares converted into common stock by SeaSide 88 (in shares)						(864)
Redemption of Series C Convertible Preferred Shares	(1,714,334)	$ 0	(1,714,334)
Redemption of Series C Convertible Preferred Shares (in shares)		0				(522)
Shares issued in conversion of Series C Preferred Shares to Common Stock (in shares)		1,815,138
Shares issued in conversion of Series C Preferred Shares to Common Stock	6,352	$ 1,816	4,536
Shares issued as Dividend to Seaside 88	90,108	$ 55	90,053
Shares issued as Dividend to Seaside 88 (in shares)		56,051
Shares issued for consulting and legal services rendered	84,956	$ 43	84,913
Shares issued for consulting and legal services rendered (in shares)		42,977
Warrants issued to Scientific Advisory Board	141,600		141,600
Common Shares issued for employee stock compensation	60,000	$ 71	59,929
Common Shares issued for employee stock compensation (in shares)		71,428
Common shares issued for debenture interest	665,497	$ 571	664,926
Common shares issued for debenture interest (in shares)		571,429
Shares issued for Directors fees	18,750	$ 10	18,740
Shares issued for Directors fees (in shares)		8,521
Dividend to Seaside 88	(96,110)	$ 0	(96,110)
Derivative Liability - retirement of Preferred Series C	968,894	0	968,894
Placement Agents Fees related to sale of Convertible Preferred shares	(165,000)	0	(165,000)
Legal Fees related to Sale of Convertible Preferred Stock	(12,500)	0	(12,500)
Net loss	(8,875,668)			(8,875,668)
Balance at Jun. 30, 2013	8,009,652	$ 47,026	46,259,420	(38,299,784)	$ 2,990	$ 0
Balance (in shares) at Jun. 30, 2013		47,026,173			2,990,000	0
Series A Preferred Shares issued for employee stock compensation	2,123,014		2,122,810		$ 204
Series A Preferred Shares issued for employee stock compensation (in shares)					203,079
Shares issued for consulting and legal services rendered	102,001	$ 31	101,970
Shares issued for consulting and legal services rendered (in shares)		29,662
Warrants issued to Scientific Advisory Board	199,849		199,849
Common Shares issued for employee stock compensation	287,860	$ 72	287,788
Common Shares issued for employee stock compensation (in shares)		71,430
Common Shares issued in connection with warrant exercises	735,624	$ 142	735,482
Common Shares issued in connection with warrant exercises (in Shares)		142,500
Common shares issued for debenture interest	2,605,716	$ 571	2,605,145
Common shares issued for debenture interest (in shares)		571,429
Shares issued for Directors fees	45,000	$ 13	44,987
Shares issued for Directors fees (in shares)		13,146
Common shares and warrants issued in connection with private placement of common stock	30,339,203	$ 6,760	30,332,443
Common shares and warrants issued in connection with private placement of common stock (in shares)		6,760,713
Common shares issues to round up financial shares arising from private placement	0	$ 6	(6)
Common shares issues to round up financial shares arising from private placement (in shares)		5,940
Placement agents fees related to sale of Common shares and Warrants	(1,820,360)		(1,820,360)
Rule 16B payment to Additional Paid in Capital	83,900		83,900
Restatement of Additional Paid in Capital to Derivative Liability	(5,740,540)		(5,740,540)
Net loss	(13,601,616)	$ 0		(13,601,616)
Balance at Jun. 30, 2014	23,369,303	$ 54,621	75,212,888	(51,901,400)	$ 3,194	$ 0
Balance (in shares) at Jun. 30, 2014		54,620,993			3,193,079	0
Series A Preferred Shares issued with Debenture Series C	1,152,297	$ 0	1,152,110		$ 187
Series A Preferred Shares issued with Debenture Series C (in shares)		0			187,000
Series A Preferred Shares issued for employee stock compensation	852,760	$ 0	852,560		$ 200
Series A Preferred Shares issued for employee stock compensation (in shares)		0			200,508
Shares issued for consulting and legal services rendered	109,360	$ 35	109,325
Shares issued for consulting and legal services rendered (in shares)		35,154
Warrants issued to Scientific Advisory Board	59,675	$ 0	59,675
Common Shares issued for employee stock compensation	125,003	$ 71	124,932
Common Shares issued for employee stock compensation (in shares)		71,430
Common Shares issued in connection with warrant exercises	6,743,297	$ 1,927	6,741,370
Common Shares issued in connection with warrant exercises (in Shares)		1,926,656
Common shares issued for debenture interest	1,502,870	$ 572	1,502,298
Common shares issued for debenture interest (in shares)		571,429
Series A Preferred Shares issued for consulting and legal services rendered	24,474		24,471		$ 3
Shares issued for Directors fees	45,000	$ 16	44,984
Shares issued for Directors fees (in shares)		16,408
Series A Preferred Shares issued for consulting and legal services rendered on November 30, 2014 (in shares)					2,858
Net loss	(2,198,172)	$ 0		(2,198,172)
Balance at Jun. 30, 2015	$ 31,785,867	$ 57,242	$ 85,824,613	$ (54,099,572)	$ 3,584	$ 0
Balance (in shares) at Jun. 30, 2015		57,242,070			3,583,445	0

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (2,198,172)	$ (13,601,616)	$ (8,875,668)
Adjustments to reconcile net loss to net cash used in operating activities
Preferred shares issued as compensation and for services	877,234	2,123,014	445,044
Common shares issued as compensation and for services	279,363	434,861	163,710
Common shares issued for interest	1,502,870	2,605,716	665,497
Warrants granted to Scientific Advisory Board	59,675	199,849	141,600
Depreciation	294,217	203,234	210,877
Amortization	8,521	8,775	8,774
Change in fair value of derivative liability	(8,529,005)	1,443,200	1,249,335
Amortization of debt discount convertible debentures	1,175,344	569,495	0
Changes in operating assets and liabilities:
Prepaid expenses	(106,336)	(56,492)	(284,206)
Prepaid expenses/accounts payable - related parties	266,741	(114,329)	344,886
Other current assets	150,000	(150,000)	0
Other long term assets	(142,531)	0	0
Accounts payable	(286,930)	113,188	24,900
Accrued expenses	(63,323)	(112,521)	107,479
Deferred interest payable	500,000	0	0
NET CASH USED IN OPERATING ACTIVITIES	(6,212,332)	(6,333,625)	(5,797,772)
CASH FLOWS FROM INVESTING ACTIVITIES:
Collateral advance for affiliate	1,000,000	0	(1,000,000)
Purchase of property and equipment	(6,760,109)	(5,231,094)	(64,931)
NET CASH USED IN INVESTING ACTIVITIES	(5,760,109)	(5,231,094)	(1,064,931)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of Convertible Debentures		5,000,000	6,000,000
Proceeds from issuance of Convertible Preferred Series C stock, net			510,963
Proceeds from issuance of common stock and warrants in connection with private placements of common stock, net of issuance costs	0	28,602,740	0
Proceeds from exercise of warrants	6,743,297	735,626	0
NET CASH PROVIDED BY FINANCING ACTIVITIES	6,743,297	34,338,366	6,510,963
NET CHANGE IN CASH AND CASH EQUIVALENTS	(5,229,144)	22,773,647	(351,740)
Cash and cash equivalents at beginning of period	36,696,892	13,923,245	14,274,985
Cash and cash equivalents at end of period	31,467,748	36,696,892	13,923,245
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:
Interest paid	480,000	480,000	197,589
Income tax paid	0	0	0
NON CASH FINANCING AND INVESTING ACTIVITIES:
Series A Preferred stock issued as discount on debentures	1,152,297	0	0
Bifurcation of embedded derivative	1,879,428	0	0
Issuance of Series C Debenture for deposit received	5,000,000	0
Common stock issued upon conversion of Series C Preferred Stock	$ 0	$ 0	$ 3,028,464

Organization and Nature of Busi

Organization and Nature of Business	12 Months Ended
	Jun. 30, 2015
Organization, Consolidation and Presentation Of Financial Statements [Abstract]
Nature of Operations [Text Block]	Note 1 – Organization and Nature of Business NanoViricides, Inc. (the “Company”) was incorporated under the laws of the State of Colorado July 25, 2000 Edot-com.com, Inc. May 12, 2005 ., On June 1, 2005, Edot-com.com, Inc. (“ECMM”) acquired Nanoviricide, Inc., a privately owned Florida corporation (“NVI”), pursuant to an Agreement and Plan of Share Exchange (the “Exchange”). Nanoviricide, Inc. was incorporated under the laws of the State of Florida on May 12, 2005. Pursuant to the terms of the Exchange, ECMM acquired NVI in exchange for an aggregate of 80,000,000 35 4,000 As a result of the Exchange transaction, the former NVI stockholders held approximately 80 On June 28, 2005, NVI was merged into its parent ECMM and the separate corporate existence of NVI ceased. Effective on the same date, Edot-com.com, Inc. changed its name to NanoViricides, Inc. and its stock symbol to “NNVC”, respectively. NanoViricides, Inc. (the “Company”), is a nano-biopharmaceutical company whose business goals are to discover, develop and commercialize therapeutics to advance the care of patients suffering from life-threatening viral infections. We are a company with several drugs in various stages of early development. Our drugs are based on several patents, patent applications, provisional patent applications, and other proprietary intellectual property held by TheraCour Pharma, Inc. (“TheraCour”), an entity owned and controlled by a significant stockholder, to which we have the necessary exclusive, worldwide licenses in perpetuity. The first agreement we executed with TheraCour Pharma on September 1, 2005, gave us an exclusive, worldwide license for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Virus (HSV), Influenza and Asian Bird Flu Virus. On February 15, 2010, the Company executed an Additional License Agreement with TheraCour. Pursuant to the Additional License Agreement, the Company was granted exclusive, worldwide licenses, in perpetuity, for technologies, developed by TheraCour, for the development of drug candidates for the treatment of Dengue viruses, Ebola/Marburg viruses, Japanese Encephalitis, viruses causing viral Conjunctivitis (a disease of the eye) and Ocular Herpes. As consideration for obtaining these exclusive licenses, we agreed to pay a onetime licensing fee equal to 2,000,000 shares (adjusted for the 3.5 to 1 reverse split) The Series A Preferred Stock is convertible, only upon sale or merger of the Company, or the sale of or license of substantially all of the Company’s intellectual property, into shares of the Company’s common stock at the rate of 3.5 shares of common stock for each share of Series A Preferred Stock. 2,000,000 2,000

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	Note 2 – Summary of Significant Accounting Policies The Company’s financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and include all adjustments necessary for the fair presentation of the Company’s financial position for the periods presented. Certain accounts in the June 30, 2014 financial statements have been reclassified to conform to the current period presentation. Basic net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, convertible preferred stock, and convertible debentures. Potentially Outstanding Dilutive Common Shares For the For the Year Year Ended Ended June 30, 2015 June 30, 2014 Stock options 535,715 535,715 Warrants 5,976,675 8,887,211 Total potentially outstanding dilutive common shares 6,512,390 9,422,926 In addition, the Company has issued Convertible Debentures, to investors. A portion of the interest required to be paid on the debentures had been paid in shares of the Company’s $ 0.001 571,428 At June 30, 2015, the estimated number of potentially dilutive shares of the Company’s common stock into which the Series B debentures can be converted based upon the conversion price of $ 3.50 1,714,286 952,381 The Company has also issued 3,583,445 0.001 3.5 12,542,058 Pursuant to the Redemption provisions of the Series C Debentures, the Company, at its sole option, shall have the right, but not the obligation, to repurchase the Debenture at any time prior to the Maturity Date (the “Redemption”). If the Company intends to repurchase the Debenture, and if the closing bid price of the Common Stock is greater than $5.25 on the Redemption Date, unless the Holder, on or prior to the Redemption Date, elects to receive the “Redemption Payment”, as that term is defined herein, the Company shall pay to the Holder: (i) 952,381 shares of Common Stock in consideration of the exchange of the principal amount of the Debenture; and (ii) any and all accrued coupon interest. If on or prior to the Redemption Date, the Holder elects to receive the Redemption Payment, or the closing bid price of the Common Stock is less than $5.25, the Company shall issue to the Holder: (i) the principal amount of the Debenture; (ii) any accrued coupon interest; (iii) additional interest of 7% per annum for the period from the date of issuance of the Debenture to the Redemption Date; and (iv) warrants to purchase 619,048 shares of Common Stock which shall expire in three years from the date of issuance at an exercise price of $6.05 per share of Common Stock (the “Redemption Warrants”, and collectively with (i) – (iii), the “Redemption Payment”). The Company shall use its best efforts to register the shares underlying the Redemption Warrants under a “shelf” registration statement, provided same is available to the Company, in accordance with the provisions of the Securities Act. For the Years Ended June 30, June 30, June 30, Calculation of basic loss per share of common stock: Net loss attributable to common stockholders $ (2,198,172) $ (13,601,616) $ (8,875,668) Denominator for basic weighted average shares of common stock 56,553,848 51,225,622 45,892,549 Basic loss per share of common stock $ (0.04) $ (0.27) $ (0.19) Calculation of diluted loss per share of common stock: Net loss attributable to common stockholders $ (2,198,172) $ (13,601,616) $ (8,875,668) Add: Loss impact of assumed conversion of Debentures (3,077,864) - (334,832) Net loss attributable to common stockholders plus assumed conversions $ (5,276,036) $ (13,601,616) $ (9,210,500) Denominator for basic weighted average shares of common stock 56,553,848 51,225,622 45,892,549 Incremental shares from assumed conversions of Debentures payable 2,666,667 - 1,714,286 Denominator for diluted weighted average shares of common stock 59,220,515 51,225,622 47,606,835 Diluted loss per share of common stock $ (0.09) $ (0.27) $ (0.19) Series B Debentures were excluded from the loss per share calculation for year ended June 30, 2014 because the impact is anti-dilutive. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheet and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, accounting for share-based compensation, accounting for derivatives and accounting for income taxes. Actual results could differ from those estimates. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value for applicable assets and liabilities, we consider the principal or most advantageous market in which we would transact and we consider assumptions market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. This guidance also establishes a fair value hierarchy to prioritize inputs used in measuring fair value as follows: • Level 1: Observable inputs such as quoted prices in active markets; • Level 2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and • Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets and would be charged to earnings. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. The Company has not recorded an impairment charge for the years ended June 30, 2015, 2014 and 2013. The Company considers all highly liquid instruments with original maturities of three months or less to be cash equivalents. Property and equipment is stated at cost and depreciated over the estimated useful lives of the assets, or lease term, if shorter, for leasehold improvement, using the straight-line method. The Company generally assigns useful lives of thirty years for assets classified as buildings, fifteen years for assets classified as land improvements and laboratory fixtures, ten years for assets classified as lab equipment, and five years for assets classified as office equipment and computers. Expenditures for major additions and betterments are capitalized. Maintenance and repairs are charged to operations as incurred. Upon sale or retirement of property and equipment, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is reflected in statements of operations. The Company amortizes the costs of intangible assets other than goodwill on a straight-line basis over their estimated useful lives, the terms of the exclusive licenses and/or agreements, or the terms of legal lives of the patents, whichever is shorter. Upon becoming fully amortized, the related cost and accumulated amortization are removed from the accounts. Research and development expenses consist primarily of costs associated with the preclinical and/ or clinical trials of drug candidates, compensation and other expenses for research and development, personnel, supplies and development materials, costs for consultants and related contract research and facility costs. Expenditures relating to research and development are expensed as incurred. The Company follows the provisions of ASC 718 – Stock Compensation The fair value of common stock issued as employee compensation is the average of the open and close share price on the date the common shares are issued. The Series A preferred shares are not traded in any market. The assumptions used to determine the fair value of the Series A preferred shares issued as employee compensation are presented in Note 8 to the financial statements. The fair value of each option award is estimated on the date of grant using a Black-Scholes option-pricing valuation model. The ranges of assumptions for inputs are as follows: · Expected term of share options and similar instruments: The expected life of options and similar instruments represents the period of time the option and/or warrant are expected to be outstanding. Pursuant to Paragraph 718-10-50-2(f)(2)(i) of the FASB Accounting Standards Codification the expected term of share options and similar instruments represents the period of time the options and similar instruments are expected to be outstanding taking into consideration of the contractual term of the instruments and employees’ expected exercise and post-vesting employment termination behavior into the fair value (or calculated value) of the instruments. Pursuant to paragraph 718-50-S99-1, it may be appropriate to use the simplified method · Expected volatility of the Company’s shares and the method used to estimate it: Expected volatility is based on the average historical volatility of the Company’s common stock over the expected term of the option. · Expected annual rate of quarterly dividends: The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the expected term of the option and similar instruments. · Risk-free rate(s): The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the expected term of the option and similar instruments. The Company’s policy is to recognize compensation cost for awards with only service conditions and a graded vesting schedule on a straight-line basis over the requisite service period for the entire award. Equity Instruments Issued to Parties other than Employees for Acquiring Goods or Services The Company follows the provisions of ASC 505 - Equity, which accounts for equity instruments issued to parties other than employees for acquiring goods or services. Pursuant to ASC 505, all transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date used to determine the fair value of the equity instrument issued is the earlier of the date on which the performance is complete or the date on which it is probable that performance will occur. The Company uses the average of the open and close market value of the Company’s common stock at each measurement date The Company has issued securities to acquire goods or services at or after the delivery of the goods or services for which it contracted. The securities when issued are fully vested and the Company has recognized such issuances as an immediate expenses. The fair value of share options and similar instruments is estimated on the date of grant using a Black-Scholes option-pricing valuation model. The ranges of assumptions for inputs are as follows: · Expected term of share options and similar instruments: The expected term of share options and similar instruments represents the contractual term of the instruments. · Expected volatility of the Company’s shares and the method used to estimate it. Expected volatility is based on the average historical volatility of the Company’s common stock over the contractual term of the option. · Expected annual rate of quarterly dividends. The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the contractual term of the option and similar instruments. · Risk-free rate(s). The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the contractual term of the option and similar instruments. The Company uses the asset and liability method of accounting for deferred income taxes. Deferred income taxes are measured by applying enacted statutory rates to net operating loss carryforwards and to the differences between the financial reporting and tax bases of assets and liabilities. Deferred tax assets are reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company recognizes uncertainty in income taxes in the financial statements using a recognition threshold and measurement attribute of a tax position taken or expected to be taken in a tax return. The Company applies the “more-likely-than-not” recognition threshold to all tax positions, commencing at the adoption date of the applicable accounting guidance, which resulted in no unrecognized tax benefits as of such date. Additionally, there have been no unrecognized tax benefits subsequent to adoption. The Company has opted to classify interest and penalties that would accrue, if any, according to the provisions of relevant tax law as selling, general, and administrative expenses, in the consolidated statement of operations. For the years ended June 30, 2015, 2014 and 2013 there was no such interest or penalty. Financial instruments that potentially subject us to a significant concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured institutions in excess of federally insured limits. The Company does not believe it is exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15 is intended to define management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. Specifically, ASU 2014-15 provides a definition of the term substantial doubt and requires an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). It also requires certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans and requires an express statement and other disclosures when substantial doubt is not alleviated. The new standard will be effective for reporting periods beginning after December 15, 2016, with early adoption permitted. Management is currently evaluating the impact of the adoption of ASU 2014-15 on the Company’s financial statements and disclosures. In April 2015, the FASB issued ASU 2015-03, Interest - Imputation of Interest (Subtopic 835-30), “Simplifying the Presentation of Debt Issuance Costs,” which requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. This ASU requires retrospective adoption and will be effective for fiscal years beginning after December 15, 2015 and for interim periods within those fiscal years. We expect the adoption of this guidance will not have a material impact on our financial statements.

Financial Condition

Financial Condition	12 Months Ended
	Jun. 30, 2015
Financial Condition Disclosure [Abstract]
Financial Condition Disclosure [Text Block]	Note 3 – Financial Condition The Company’s financial statements have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities and commitments in the normal course of business. The Company has an accumulated deficit at June 30, 2015 ($54,099,572) and had a net loss and net cash used in operating activities for the fiscal year then ended. In addition, the Company has not generated any revenues and no revenues are anticipated in the foreseeable future. Since May 2005, the Company has been engaged exclusively in research and development activities focused on developing targeted antiviral drugs. The Company has not yet commenced any product commercialization. Such losses are expected to continue for the foreseeable future and until such time, if ever, as the Company is able to attain sales levels sufficient to support its operations. There can be no assurance that the Company will achieve or maintain profitability in the future. As of June 30, 2015 the Company had cash and cash equivalents of $ 31,467,748 While the Company continues to incur significant operating losses with significant capital requirements, the Company has been able to finance its business through sale of its securities. The Company may require additional capital to finance planned and currently unplanned capital costs and additional staffing requirements during the next 24 months. The Company has in the past adjusted its priorities and goals in line with the cash on hand and capital availability. The Company believes it can adjust its priorities of drug development and its plan of operations as necessary, if it is unable to raise additional funds.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Jun. 30, 2015
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	Note 4 – Related Party Transactions Related Parties Related parties with whom the Company had transactions are: Related Parties Relationship Anil R. Diwan Chairman, President, significant stockholder and director Eugene Seymour CEO, significant stockholder, director TheraCour Pharma, Inc. An entity owned and controlled by significant stockholder Inno-Haven, LLC An entity owned and controlled by significant stockholder Milton Boniuk, MD Director and significant stockholder For the Years Ended June 30, June 30, During the reporting period, the Company acquired 1 Controls Drive Shelton Ct from Inno-Haven, LLC $ 4,222,549 $ - During the reporting period, Inno-Haven, LLC, acquired property and equipment on behalf of the Company from third party vendors and sold such property and equipment, at cost, to the Company $ - $ 4,500,000 During the reporting period, TheraCour Pharma, Inc. acquired property and equipment on behalf of the Company from third party vendors and sold such property and equipment, at cost, to the Company $ 255,019 $ 528,720 Accounts Payable Related Party June 30, June 30, Pursuant to an Exclusive License Agreement and an Additional License Agreement we entered into with TheraCour Pharma, Inc., (TheraCour), the Company was granted exclusive licenses in perpetuity for technologies developed by TheraCour for the virus types: HIV, HCV, Herpes, Asian (bird) flu, Influenza and rabies, and others. In consideration for obtaining these exclusive licenses, we agreed: (1) that TheraCour can charge its costs (direct and indirect) plus no more than 30% of direct costs as a Development Fee and such development fees shall be due and payable in periodic installments as billed. (2) we will pay $25,000 per month for usage of lab supplies and chemicals from existing stock held by TheraCour, (3) we will pay $2,000 per month or actual costs, whichever is higher for other general and administrative expenses incurred by TheraCour on our behalf. Accounts payable due TheraCour Pharma Inc. (including a two (2) month security advance): $ 316,196 $ 49,455 Research and Development Costs Paid to Related Parties For the Year ended June 30, June 30, June 30, Development fees and other costs charged by and paid to TheraCour Pharma, Inc. pursuant to exclusive License Agreements between TheraCour and the Company for the development of the Company’s drug pipeline. No royalties are due TheraCour from the Company at June 30, 2015, 2014 and 2013 $ 2,403,126 $ 2,611,754 $ 1,988,046 Long Term Debenture Payable to a Director June 30, June 30, Series B Convertible Debentures - Milton Boniuk $ 4,000,000 $ 4,000,000 Series C Convertible Debentures - Milton Boniuk 5,000,000 - Total Long Term Debentures Payable to a Director $ 9,000,000 $ 4,000,000 Debenture Interest Paid to a Director June 30, June 30, Debenture interest was paid or recognized to Milton Boniuk, or an entity controlled by him, pursuant to the terms of the Series B and Series C Convertible Debentures. Coupon interest payable on $5,000,000 Series C Convertible Debentures and deferred. The deferred interest will be paid out quarterly over the remaining term of the debenture: Deferred interest payable - short term $ 166,667 $ - Deferred interest payable - long term $ 333,333 $ - Stock interest paid in kind on Series B Convertible Debentures to Dr. Milton Boniuk and recognized at fair value was $1,001,532, $ 1,730,763 665,497 Coupon interest paid on the Series B Debentures to Dr. Milton Boniuk for the years ending June 30, 2015, 2014 and 2013 was $ 320,000 320,000 197,589

Property and Equipment

Property and Equipment	12 Months Ended
	Jun. 30, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	Note 5 – Property and Equipment June 30, June 30, Land $ 260,000 $ - Building GMP Facility 7,905,938 3,099,780 Office Equipment 65,241 30,048 Furniture and Fixtures 1,400 1,400 Lab Equipment & fixtures 5,264,272 3,605,514 Total Property and Equipment 13,496,851 6,736,742 Less Accumulated Depreciation (1,534,203) (1,239,986) Property and Equipment, Net $ 11,962,648 $ 5,496,756 Depreciation expense for the years ended June 30, 2015, 2014 and 2013 was $ 294,217 203,234 210,877 On December 31, 2014, the Company entered into and consummated an Agreement for the Purchase and Sale of a cGMP-compliant pilot manufacturing and lab facility at 1 Controls Drive, Shelton, Connecticut. The purchase price of the facility was comprised solely of the repayment of the direct costs of the seller, Inno-Haven, LLC (“Inno-Haven”), an entity owned and controlled by a significant stockholder, incurred in acquiring and renovating the property and the facility plus Inno-Haven’s closing costs in connection with the sale. The purchase price consisted of the repayment of Inno-Haven’s acquisition and renovation expenses of $ 81,230

Trademark and Patents

Trademark and Patents	12 Months Ended
	Jun. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets Disclosure [Text Block]	Note 6 – Trademark and Patents June 30, June 30, Trademarks and Patents $ 458,954 $ 458,954 Less Accumulated Amortization (59,217) (50,696) Trademarks and Patents, Net $ 399,737 $ 408,258 Amortization expense amounted to $ 8,521 8,775 8,774 The Company amortizes our trademarks and patents over their expected original useful lives of 17 2016 $ 8,521 2017 8,521 2018 8,521 2019 8,521 2020 8,521 Thereafter 357,132 Total amortization $ 399,737

Convertible Debentures and Inve

Convertible Debentures and Investor Warrants	12 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	Note 7 – Convertible Debentures and Investor Warrants On February 1, 2013, the Company raised gross proceeds of $ 6,000,000 4,000,000 4 8 571,429 571,429 3.50 3 3.50 The Company can prepay the debentures, in which case the base interest rate shall increase by a 7% prepayment penalty. The Company agreed to use its best efforts to register the interest shares and the shares issuable from the interest warrants under a “shelf” registration statement provided same is available, in accordance with the provisions of the Securities Act June 30, June 30, Proceeds $ 6,000,000 $ 6,000,000 Debt discount for bifurcated derivative (2,735,310) (2,735,310) 3,264,690 3,264,690 Amortization of debt discount 1,435,892 772,878 Debenture payable - Series B, net $ 4,700,582 $ 4,037,568 The debenture contains embedded derivatives which are not clearly and closely related to the host instrument. The embedded derivatives are bifurcated from the host debt instrument and treated as a liability. The single compound embedded derivative features valued include the: 1. Principal conversion feature at maturity based on a fixed conversion price subject to standard adjustments. 2. Redemption additional interest and Redemption Warrants offering. 3. Additional interest shares and interest warrants. For the years ended June 30, 2015, 2014 and 2013, the Company recognized amortization of the debt discount as an additional interest charge to “Discount on convertible debentures” in the amounts of $ 663,014 569,495 203,383 The Company used a lattice model that values the compound embedded derivatives of the Series B Convertible Debenture based on a probability weighted discounted cash flow model at June 30, 2015 and 2014. The following assumptions were used for the valuation of the compound embedded derivative at June 30, 2015 and 2014: ⋅ The balance of the Series B Convertible Debenture as of issuance and June 30, 2015 and 2014 is $ 6,000,000 ⋅ The underlying stock price was used as the fair value of the common stock. The stock price decreased to $ 1.75 3.50 4.23 3.50 ⋅ The projected annual volatility was based on the Company historical volatility: 1 year 06/30/2015 62 06/30/2014 92 · An event of default would occur 0% of the time, increasing 1.00% per month to a maximum of 10% ⋅ The Company would redeem the debentures projected initially at 0 1.0 20.0 ⋅ The Holder would automatically convert the interest if the Company was not in default and its shares value would be equivalent to the cash value; ⋅ The Holder would automatically convert the debenture at maturity if the registration was effective and the Company was not in default. ⋅ The weighted cost of capital discount rate (based on the market value of the transactions at issuance) adjusted for changes in the risk free rate is 21.60 ⋅ Even through the shares are restricted the underlying assumption is that any restriction on resale will be removed either through registration or the passage of time at the time of issuance. The fair value of the compound embedded derivatives of the Series B Convertible Debenture at June 30, 2015 and 2014 was $ 366,764 5,699,703 On July 2, 2014 (the “Closing Date”), the Company accepted a subscription in the amount of $ 5,000,000 10 5,000,000 June 30, 2018 0.001 5.25 5.25 952,381 7 619,048 6.05 On July 2, 2014, in conjunction with the issuance of the Company’s Series C Convertible Debentures, the Company issued 187,000 1,645,606 1,152,297 1,152,297 1,879,428 512,330 The following represents the balance of the Debenture payable – Series C, net of discount at June 30, 2015: Proceeds $ 5,000,000 Debt discount Series A Preferred (1,152,297) Embedded derivative (1,879,428) 1,968,275 Amortization of debt discount for the year ended June 30, 2015 512,330 Balance at June 30, 2015 $ 2,480,605 The Company used a lattice model that values the compound embedded derivatives of the Series C Convertible Debenture based on a probability weighted discounted cash flow model at issuance and June 30, 2015. The following assumptions were used for the valuation of the compound embedded derivative at July 2, 2014: ⋅ The balance of the Series C Convertible Debenture as of issuance is $ 5,000,000 ⋅ The underlying stock price was used as the fair value of the common stock. The stock price at issuance was $ 3.00 . 5.25 ⋅ The projected annual volatility was 92 ⋅ An event of default would occur 0% of the time, increasing 1.00% per month to a maximum of 10% ⋅ The Company would redeem the debentures projected initially at 0 1.0 5 .0% ⋅ The Holder would automatically convert the interest if the Company was not in default and its shares value would equivalent to the cash value; ⋅ The Holder would automatically convert the debenture at maturity if the registration was effective and the Company was not in default; ⋅ The weighted cost of capital discount role (based on the market value of the transactions at issuance) adjusted for changes in the risk free rate is 21.86 ⋅ Even through the shares are restricted the underlying assumption is that any restriction on resale will be removed either through registration or the passage of time at the time of issuance. The following assumptions were used for the valuation of the compound embedded derivative at June 30, 2015: ⋅ The balance of the Series C Convertible Debenture as of June 30, 2015 is $ 5,000,000 ⋅ The underlying stock price was used as the fair value of the common stock. The stock price decreased to $ 1.75 5.25 ⋅ The projected annual volatility was 62 ⋅ An event of default would occur 0% of the time, increasing 1.00% per month to a maximum of 10% ⋅ The Company would redeem the debentures projected initially at 0 1.0 5.0 ⋅ The Holder would automatically convert the interest if the Company was not in default and its shares value was equivalent to the cash value; ⋅ The Holder would automatically convert the debenture at maturity if the registration was effective and the Company was not in default; ⋅ The weighted cost of capital discount rate (based on the market value of the transaction at issuance) adjusted for changes in the risk free rate is 21.97 ⋅ Even through the shares are restricted the underlying assumption is that any restriction on resale will be removed either through registration or the passage of time at the time of issuance. The fair value of the compound embedded derivatives of the Series C Convertible Debenture at issuance and June 30, 2015 was $ 1,879,428 476,289

Equity Transactions

Equity Transactions	12 Months Ended
	Jun. 30, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Note 8 – Equity Transactions On September 3, 2013, effective September 10, 2013, NanoViricides, Inc. filed a Certificate of Change to its Articles of Incorporation pursuant to Section 78.209 of the Nevada Revised Statutes (the “Amendment”). The Amendment effectuated a reverse stock split of the Company’s common stock, par value $ 0.001 Fiscal Year Ending June 30, 2013 Transactions For the year ended June 30, 2013, the Board of Directors authorized the issuance of 571,429 .001 665,497 For the year ended June 30, 2013, the Board of Directors authorized the issuance of 71,428 .001 60,000 For the year ended June 30, 2013, the Board of Directors authorized the issuance of 169,643 .001 445,044 For the year ended June 30, 2013, the Scientific Advisory Board (SAB) was granted warrants to purchase 68,572 141,600 For the year ended June 30, 2013, the Company’s Board of Directors authorized the issuance of 42,977 84,956 For the year ended June 30, 2013, the Company’s Board of Directors authorized the issuance of 8,521 18,750 Fiscal Year Ending June 30, 2014 Transactions On September 9, 2013, the Company entered into a Securities Purchase Agreement (the “Agreement”) with certain purchasers (the “Purchasers”), relating to the offering and sale (the “Offering”) of units (“Units”) at the aggregate purchase price of $ 3.50 0.001 5.25 On September 12, 2013, post reverse split the Company and the Purchasers consummated the purchase and sale of the Securities (the “Closing”), and the Company raised gross proceeds of $ 10,308,996 618,540 2,945,428 35,357 0.001 185,624 75,000 25,000 0.001 393,750 131,750 The Offering was made pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-184626), which was declared effective by the Securities and Exchange Commission on December 21, 2012. The Company, pursuant to Rule 424(b) under the Securities Act of 1933, has filed with the Securities and Exchange Commission a prospectus supplement relating to the Offering. In connection with the Offering, pursuant to a Placement Agency Agreement dated September 9, 2013 among Midtown Partners & Co., LLC and Chardan Capital Markets, LLC (collectively, the “Placement Agents”), the Company paid the Placement Agents an aggregate cash fee representing 6% (3% each) of the gross Purchase Price paid by the Purchasers and warrants to purchase an aggregate of 2% (1% each) of the number of shares of Common Stock sold in the Offering (the “Compensation Warrants”) and substantially similar to the Warrants, at an exercise price equal to $5.25 per share. 113,696 113,696 On September 25, 2013, the Company’s Common Stock began trading on the NYSE MKT exchange under the symbol NNVC. On January 21, 2014, the Company entered into a Securities Purchase Agreement (the “Agreement”) with certain purchasers (the “Purchasers”), relating to the offering and sale (the “Offering”) of units (“Units”) at the aggregate purchase price of $ 5.25 The price per Unit was equal to a four percent (4%) discount to the 20-day VWAP of the Company’s stock price on Friday, January 17, 2014. The exercise price of the Warrant was equal to the closing price of the Company’s stock on Friday, January 17, 2014. Each Unit consisted of one share of the Company’s common stock, par value $0.001 per share (the “Common Stock”) and Sixty-Five Hundredths (65/100) of a warrant to purchase one share of Common Stock (“Warrant”), 6.05 On January 24, 2014, the Company and the Purchasers consummated the purchase and sale of the Securities (the “Closing”) of 3,815,285 2,479,935 20,030,207 1,200,000 The Offering was made pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-184626), which was declared effective by the Securities and Exchange Commission on December 21, 2012 and Form S-3MEF (File No. 333-193439). In connection with the Offering, pursuant to a Placement Agency Agreement dated January 20, 2014 among Midtown Partners & Co., LLC and Chardan Capital Markets, LLC (collectively, the “Placement Agents”), the Company paid the Placement Agents an aggregate cash fee representing 6% of the gross Purchase Price paid by the Purchasers and warrants to purchase an aggregate of 2% of the number of shares of Common Stock sold in the Offering (the “Compensation Warrants”) representing two percent of the Shares and substantially similar to the Warrants, at an exercise price equal to $6.05 per share. Unregistered Securities In December, 2013, the Company issued 7,143 3.50 For the year ended June 30, 2014, the Board of Directors authorized the issuance of 571,429 .001 2,605,716 For the year ended June 30, 2014, the Company’s Board of Directors authorized the issuance of 29,662 102,001 For the year ended June 30, 2014, the Company’s Board of Directors authorized the issuance of 13,146 45,000 For the year ended June 30, 2014 the Board of Directors authorized the issuance of 203,079 .001 2,123,014 For the year ended June 30, 2014, the Company authorized the issuance of 71,430 .001 287,860 For the year ended June 30, 2014 the Scientific Advisory Board (SAB) was granted warrants to purchase 72,439 199,849 June 30, Expected life (year) 4 Expected volatility 78.39%-98.09 % Expected annual rate of quarterly dividends 0.00 % Risk-free rate(s) .37-1.12 % There is currently no market for the shares of Series A Preferred Stock and they can only be converted into shares of common stock upon a change of control of the Company. The Company, therefore, estimated the fair value of the Series A Preferred stock granted to various employees on the date of grant. The Preferred stock fair value is based on the greater of i) the converted value to common at a ratio of 1:3.5; or ii) the value of the voting rights since the holder would lose the voting rights upon conversion. The conversion of the shares is triggered either by the Company or a Change of Control. The valuation of the Series A Preferred Stock as of 6/30/14 used the following inputs: a. The common stock price (post-reverse split) was in the range $2.45 to $3.90; b. 47,026,173 54,614,930 2,572 169,644 c. A 5.36% premium over the common shares for the voting preferences; d. 54,506,459 62,208,499 e. The conversion value is based on an assumption for calculation purposes only of a Change of Control in 4 years from 3/1/13 and a restricted term of 3.67 to 2.67 years; f. 42.87% to 27.11% restricted stock discount (based on a restricted stock analysis and call-put analysis curve: 121.97% to 265.70% volatility, 0.37% to 1.62% risk-free rate) applied to the converted common. Based upon the above assumptions the estimated fair value of the preferred shares issued to Company employees as a whole for the fiscal year ended June 30, 2014 was calculated to be $ 2,123,014 Fiscal Year Ending June 30, 2015 Transactions On July 17, 2014, the Company filed a registration statement on Form S-3 (the “Form S-3”) registering an aggregate of 3,071,986 1,926,656 3.50 6,743,297 On February 1, 2015 the Company’s Board of Directors authorized the issuance of 571,433 0.001 1,502,870 Unregistered Securities As discussed in Note 7, on July 2, 2014, in conjunction with the issuance of the Company’s Series C Convertible Debentures, the Company issued 187,000 1,152,297 For the year ended June 30, 2015, the Scientific Advisory Board was granted fully vested warrants to purchase 68,592 2.00 5.02 59,675 Expected life (year) 4 Expected volatility 37.44% -45.84 % Expected annual rate of quarterly dividends 0.00 % Risk-free rate(s) 1.20 - 1.67 % For the year ended June 30, 2015, the Company’s Board of Directors authorized the issuance of 35,154 109,360 For the year ended June 30, 2015, the Company’s Board of Directors authorized the issuance of 16,408 45,000 For the year ended June 30, 2015, the Company’s Board of Directors authorized the issuance of 2,858 24,474 For the year ended June 30, 2015, the Company's Board of Directors authorized the issuance of 71,430 125,003 For the year ended June 30, 2015, the Company’s Board of Directors authorized the issuance of 200,508 852,760 Date Shares Value 7/31/2014 2,572 $ 25,821 8/31/2014 2,572 27,560 9/30/2014 2,572 19,602 10/31/2014 2,572 18,765 11/30/2014 2,572 22,025 12/31/2014 2,572 18,849 1/31/2015 2,572 16,501 2/28/2015 2,572 15,943 3/31/2015 2,572 16,299 4/30/2015 2,572 14,124 5/31/2015 2,572 11,460 6/30/2015 172,216 645,811 200,508 $ 852,760 There is currently no market for the shares of Series A Preferred Stock and they can only be converted into shares of common stock upon a Change of Control of the Company as more fully described in the Certificate of Designation. The Company, therefore, estimated the fair value of the Series A Preferred stock granted to various employees and others on the date of grant. The Series A Preferred stock fair value is based on the greater of i) the converted value to common at a ratio of 1:3.5 a. The common stock price was in the range $2.29 to $1.55; b. The calculated weighted average number of shares of common stock in the period; c. A 5.36% premium over the common shares for the voting preferences; d. The calculated weighted average number of total voting shares and the monthly shares representing voting rights of 4.896% to 5.046% of the total; e. The conversion value is based on an assumption for calculation purposes only of a Change of Control in 4 years from March 1, 2013 and a remaining restricted term of 1.92 to 1.67 years; f. 30.86% to 31.42% restricted stock discount (based on a restricted stock analysis and call-put analysis curve: 63.52% to 69.38% volatility, 0. 22% to 0.26% risk free rate) applied to the converted common.

Stock Options and Warrants

Stock Options and Warrants	12 Months Ended
	Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	Note 9 – Stock Options and Warrants Stock Options Number of Weighted Weighted Aggregate Outstanding at June 30, 2013 535,715 0.35 2.23 1,521,429 Granted - - - - Exercised - - - - Expired - - - - Canceled - - - - Outstanding at June 30, 2014 535,715 $ 0.35 1.23 $ 2,094,643 Granted - - - - Exercised - - - - Expired - - - - Canceled - - - - Outstanding at June 30, 2015 535,715 $ 0.35 0.23 $ 749,997 Stock Warrants Number of Weighted Weighted Aggregate Outstanding at June 30, 2013 3,400,559 4.025 0.86 134,559 Granted 5,629,152 5.63 4.37 - Exercised 142,500 3.50 - - Expired - - - - Canceled - - - - Outstanding and exercisable at June 30, 2014 8,887,211 $ 5.01 2.78 $ 2,278,458 Granted 68,592 3.63 - - Exercised 1,926,656 3.50 - - Expired 1,052,472 3.50 - - Canceled - - - - Outstanding and exercisable at June 30, 2015 5,976,675 $ 5.14 3.20 $ 19,000 Of the above warrants; 345,720 June 30, 2016 68,571 June 30, 2017 68,570 June 30,2018 5,493,814 June 30, 2019

Fair Value Measurement

Fair Value Measurement	12 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	Note 10 – Fair Value Measurement Fair value measurements At June 30, 2015 and 2014, the fair value of derivative liabilities is estimated using a lattice model that is based on the individual characteristics of our warrants, preferred and common stock, the derivative liability on the valuation date as well as assumptions for volatility, remaining expected life, risk-free interest rate and, in some cases, credit spread. The derivative liabilities are the only Level 3 fair value measures. Fair Value Measurements at June 30, 2015: (Level 1) (Level 2) (Level 3) Derivative liability – Series B debentures $ - - $ 366,764 Derivative liability – Series C debentures - - 476,289 Derivative liability – warrants - - 3,442,754 Total derivatives $ - $ - $ 4,285,808 Fair Value Measurements at June 30, 2014: (Level 1) (Level 2) (Level 3) Derivative liability – Series B debentures $ - $ - 5,699,703 Derivative liability - warrants - - 5,235,682 Total derivatives $ - $ - $ 10,935,385 In conjunction with the Company’s registered direct offerings of Units, consisting of the Company’s common stock and warrants, on September 12, 2013 and January 24, 2014 the Company issued 2,945,428 2,479,935 2,910,071 2,379,935 58,910 76,306 68,592 The Company accounts for stock purchase warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreements. Under applicable accounting guidance, stock warrants must be accounted for as derivative financial instruments if the warrants contain full-ratchet anti-dilution provisions, which preclude the warrants from being considered indexed to its own stock. The warrants described above contained a full-ratchet anti-dilution feature and are thus classified as a derivative liability. The Company used a lattice model to calculate the fair value of the derivative warrants based on a probability weighted discounted cash flow model. This model is based on future projections of the various potential outcomes. The features that were analyzed and incorporated into the model included the exercise and full reset features. The Warrants were valued as of issuance, exercise, and the quarterly periods with the following assumptions: - The 5 5.25 6.05 - The stock price would fluctuate with the Company projected volatility. - The Holder would exercise the warrant as they become exercisable (effective registration at issuance) at target prices of the higher of 2 times 2 times - The next capital raise would fluctuate with an annual volatility. The projected volatility curve was based on historical volatilities of the Company for the valuation periods. 1 Year 9/12/13 87 % 1/24/14 93 % 6/30/14 92 % 6/30/15 62 % The primary factors driving the economic value of options are stock price; stock volatility; reset events and exercise behavior. Projections of these variables over the remaining term of the warrant are either derived or based on industry averages. Based on the above, a probability was assigned to each scenario for each future period, and the appropriate derivative value was determined for each scenario. The option value was then probability weighted and discounted to the present. Fair Value Measurement Unobservable Inputs Derivative Derivative Derivative Beginning balance at July 1, 2013 $ 3,751,645 $ - $ - Additions during the year - - 5,740,540 Change in fair value 1,948,058 - (504,858) Transfer in and/or out of Level 3 - - - Balance at July 1, 2014 $ 5,699,703 $ - $ 5,235,682 Additions during the year - 1,879,428 - Change in fair value (5,332,938) (1,403,139) (1,792,928) Transfer in and/or out of Level 3 - - - Balance at June 30, 2015 $ 366,765 $ 476,289 $ 3,442,754

Income Tax Provision

Income Tax Provision	12 Months Ended
	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	Note 11 – Income Tax Provision Deferred Tax Assets/(Liabilities) The Company has no current tax expense due to its losses. 6.30.2015 6.30.2014 Federal Statutory Rate -34.00 % -34.00 % Permanent Differences -37.00 % -37.00 % Valuation Allowance 71.00 % 71.00 % Effective Tax Rate 0.00 % 0.00 % 6.30.2015 6.30.2014 Net operating losses 16,394,801 13,408,064 Research and Development Credit 4,800,186 3,422,745 Other 5,214,064 4,178,211 Total gross deferred tax assets 26,409,051 21,009,020 Less Valuation allowance (26,409,051) (21,009,020) Net deferred tax assets - - At June 30, 2015 and 2014, the Company has recorded a full valuation allowance against its net deferred tax assets of approximately $ 26,409,000 21,009,000 5,400,000 As of June 30, 2015, the Company has approximately $ 43,400,000 4,177,000 623,000 Due to the change in ownership provisions of the Internal Revenue Code, the availability of the Company’s net operating loss carry forwards could be subject to annual limitations against taxable income in future periods, which could substantially limit the eventual utilization of such carry forwards. The Company has not analyzed the historical or potential impact of its equity financings on beneficial ownership and therefore no determination has been made whether the net operating loss carry forward is subject to any Internal Revenue Code Section 382 limitation. To the extent there is a limitation, there could be a reduction in the deferred tax asset with an offsetting reduction in the valuation allowance. The Company applies the elements of FASB ASC 740-10 “Income Taxes - Overall” regarding accounting for uncertainty in income taxes. This clarifies the accounting for uncertainty in income taxes recognized in financial statements and required impact of a tax position to be recognized in the financial statements if that position is more likely than not of being sustained by the taxing authority. As of June 30, 2015 the Company did not have any unrecognized tax benefits and has not accrued any interest or penalties through 2015. The Company does not expect to have any unrecognized tax benefits within the next twelve months. The Company’s policy is to recognize interest and penalties related to tax matters within the income tax provision.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Note 12 – Commitments and Contingencies The Company maintains facilities located at 135 Wood Street, West Haven, Connecticut, that includes approximately 7,000 8,695 February 28, 2011 Total rent expense at 135 Wood Street, West Haven, Connecticut amounted to $ 104,340 104,340 Legal Proceedings There are no pending legal proceedings against the Company to the best of the Company’s knowledge as of the date hereof and to the Company’s knowledge, no action, suit or proceeding has been threatened against the Company. Employment Agreements On March 3, 2010, the Company entered into employment agreements with its two executive officers, Eugene Seymour, Chief Executive Officer and Chief Financial Officer and Anil Diwan, President and Chairman of Board. Both agreements provided a minimum annual base salary of $ 250,000 275,000 5,000,000 300,000 300,000 As additional compensation to each officer, under the employment agreements, the Company issued 71,430 On March 3, 2010, the Company entered into an employment agreement with Dr. Jayant Tatake to serve as Vice President of Research and Development. The employment agreement provides for a term of four years with a base salary of $ 150,000 26,786 35,715 26,786 35,715 On March 3, 2010, the Company entered into an employment agreement with Dr. Randall Barton to serve as Chief Scientific Officer. The employment agreement provided for a term of four years with a base salary of $ 150,000 35,715 35,715 On May 30, 2013, the Company entered into an Employment Agreement with Meeta Vyas to serve as its Chief Financial Officer. The employment agreement provides for a base salary of $ 9,000 2,572 10,800 License Agreements The Company is dependent upon its license agreement with TheraCour Pharma, Inc. (See Note 4). If the Company lost the right to utilize any of the proprietary information that is the subject of the TheraCour Pharma license agreement on which it depends, the Company will incur substantial delays and costs in development of its drug candidates.

Subsequent Events

Subsequent Events	12 Months Ended
	Jun. 30, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Note 14 – Subsequent Events On July 21, 2015 the Company entered into employment agreements with Anil Diwan, PhD, the Company’s founder, President and Chairman, and Eugene Seymour, MD, MPH, the Company’s Chief Executive Officer and Director effective July 1, 2015. The Company and Dr. Diwan agreed Dr. Diwan would continue to serve as the Company’s President and Chairman of the Board of Directors for a term of three years. Dr. Diwan’s compensation would be $ 350,000 375,000 400,000 225,000 75,000 The Company and Dr. Seymour agreed that Dr. Seymour would continue to serve as the Company’s Chief Executive Officer and Director for a term of three years. Dr. Seymour’s compensation would be $ 350,000 375,000 400,000 225,000 75,000

Summary of Significant Accoun20

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	The Company’s financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and include all adjustments necessary for the fair presentation of the Company’s financial position for the periods presented.
Reclassification, Policy [Policy Text Block]	Certain accounts in the June 30, 2014 financial statements have been reclassified to conform to the current period presentation.
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Common Share Basic net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, convertible preferred stock, and convertible debentures. Potentially Outstanding Dilutive Common Shares For the For the Year Year Ended Ended June 30, 2015 June 30, 2014 Stock options 535,715 535,715 Warrants 5,976,675 8,887,211 Total potentially outstanding dilutive common shares 6,512,390 9,422,926 In addition, the Company has issued Convertible Debentures, to investors. A portion of the interest required to be paid on the debentures had been paid in shares of the Company’s $ 0.001 571,428 At June 30, 2015, the estimated number of potentially dilutive shares of the Company’s common stock into which the Series B debentures can be converted based upon the conversion price of $ 3.50 1,714,286 952,381 The Company has also issued 3,583,445 0.001 3.5 12,542,058 Pursuant to the Redemption provisions of the Series C Debentures, the Company, at its sole option, shall have the right, but not the obligation, to repurchase the Debenture at any time prior to the Maturity Date (the “Redemption”). If the Company intends to repurchase the Debenture, and if the closing bid price of the Common Stock is greater than $5.25 on the Redemption Date, unless the Holder, on or prior to the Redemption Date, elects to receive the “Redemption Payment”, as that term is defined herein, the Company shall pay to the Holder: (i) 952,381 shares of Common Stock in consideration of the exchange of the principal amount of the Debenture; and (ii) any and all accrued coupon interest. If on or prior to the Redemption Date, the Holder elects to receive the Redemption Payment, or the closing bid price of the Common Stock is less than $5.25, the Company shall issue to the Holder: (i) the principal amount of the Debenture; (ii) any accrued coupon interest; (iii) additional interest of 7% per annum for the period from the date of issuance of the Debenture to the Redemption Date; and (iv) warrants to purchase 619,048 shares of Common Stock which shall expire in three years from the date of issuance at an exercise price of $6.05 per share of Common Stock (the “Redemption Warrants”, and collectively with (i) – (iii), the “Redemption Payment”). The Company shall use its best efforts to register the shares underlying the Redemption Warrants under a “shelf” registration statement, provided same is available to the Company, in accordance with the provisions of the Securities Act. For the Years Ended June 30, June 30, June 30, Calculation of basic loss per share of common stock: Net loss attributable to common stockholders $ (2,198,172) $ (13,601,616) $ (8,875,668) Denominator for basic weighted average shares of common stock 56,553,848 51,225,622 45,892,549 Basic loss per share of common stock $ (0.04) $ (0.27) $ (0.19) Calculation of diluted loss per share of common stock: Net loss attributable to common stockholders $ (2,198,172) $ (13,601,616) $ (8,875,668) Add: Loss impact of assumed conversion of Debentures (3,077,864) - (334,832) Net loss attributable to common stockholders plus assumed conversions $ (5,276,036) $ (13,601,616) $ (9,210,500) Denominator for basic weighted average shares of common stock 56,553,848 51,225,622 45,892,549 Incremental shares from assumed conversions of Debentures payable 2,666,667 - 1,714,286 Denominator for diluted weighted average shares of common stock 59,220,515 51,225,622 47,606,835 Diluted loss per share of common stock $ (0.09) $ (0.27) $ (0.19) Series B Debentures were excluded from the loss per share calculation for year ended June 30, 2014 because the impact is anti-dilutive.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheet and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, accounting for share-based compensation, accounting for derivatives and accounting for income taxes. Actual results could differ from those estimates.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value for applicable assets and liabilities, we consider the principal or most advantageous market in which we would transact and we consider assumptions market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. This guidance also establishes a fair value hierarchy to prioritize inputs used in measuring fair value as follows: • Level 1: Observable inputs such as quoted prices in active markets; • Level 2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and • Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Long-Lived Assets Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets and would be charged to earnings. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. The Company has not recorded an impairment charge for the years ended June 30, 2015, 2014 and 2013.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid instruments with original maturities of three months or less to be cash equivalents.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment is stated at cost and depreciated over the estimated useful lives of the assets, or lease term, if shorter, for leasehold improvement, using the straight-line method. The Company generally assigns useful lives of thirty years for assets classified as buildings, fifteen years for assets classified as land improvements and laboratory fixtures, ten years for assets classified as lab equipment, and five years for assets classified as office equipment and computers. Expenditures for major additions and betterments are capitalized. Maintenance and repairs are charged to operations as incurred. Upon sale or retirement of property and equipment, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is reflected in statements of operations.
Intangible Assets Other Than Goodwill [Policy Text Block]	Intangible Assets Other Than Goodwill The Company amortizes the costs of intangible assets other than goodwill on a straight-line basis over their estimated useful lives, the terms of the exclusive licenses and/or agreements, or the terms of legal lives of the patents, whichever is shorter. Upon becoming fully amortized, the related cost and accumulated amortization are removed from the accounts.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development expenses consist primarily of costs associated with the preclinical and/ or clinical trials of drug candidates, compensation and other expenses for research and development, personnel, supplies and development materials, costs for consultants and related contract research and facility costs. Expenditures relating to research and development are expensed as incurred.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation The Company follows the provisions of ASC 718 – Stock Compensation The fair value of common stock issued as employee compensation is the average of the open and close share price on the date the common shares are issued. The Series A preferred shares are not traded in any market. The assumptions used to determine the fair value of the Series A preferred shares issued as employee compensation are presented in Note 8 to the financial statements. The fair value of each option award is estimated on the date of grant using a Black-Scholes option-pricing valuation model. The ranges of assumptions for inputs are as follows: · Expected term of share options and similar instruments: The expected life of options and similar instruments represents the period of time the option and/or warrant are expected to be outstanding. Pursuant to Paragraph 718-10-50-2(f)(2)(i) of the FASB Accounting Standards Codification the expected term of share options and similar instruments represents the period of time the options and similar instruments are expected to be outstanding taking into consideration of the contractual term of the instruments and employees’ expected exercise and post-vesting employment termination behavior into the fair value (or calculated value) of the instruments. Pursuant to paragraph 718-50-S99-1, it may be appropriate to use the simplified method · Expected volatility of the Company’s shares and the method used to estimate it: Expected volatility is based on the average historical volatility of the Company’s common stock over the expected term of the option. · Expected annual rate of quarterly dividends: The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the expected term of the option and similar instruments. · Risk-free rate(s): The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the expected term of the option and similar instruments. The Company’s policy is to recognize compensation cost for awards with only service conditions and a graded vesting schedule on a straight-line basis over the requisite service period for the entire award. Equity Instruments Issued to Parties other than Employees for Acquiring Goods or Services The Company follows the provisions of ASC 505 - Equity, which accounts for equity instruments issued to parties other than employees for acquiring goods or services. Pursuant to ASC 505, all transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date used to determine the fair value of the equity instrument issued is the earlier of the date on which the performance is complete or the date on which it is probable that performance will occur. The Company uses the average of the open and close market value of the Company’s common stock at each measurement date The Company has issued securities to acquire goods or services at or after the delivery of the goods or services for which it contracted. The securities when issued are fully vested and the Company has recognized such issuances as an immediate expenses. The fair value of share options and similar instruments is estimated on the date of grant using a Black-Scholes option-pricing valuation model. The ranges of assumptions for inputs are as follows: · Expected term of share options and similar instruments: The expected term of share options and similar instruments represents the contractual term of the instruments. · Expected volatility of the Company’s shares and the method used to estimate it. Expected volatility is based on the average historical volatility of the Company’s common stock over the contractual term of the option. · Expected annual rate of quarterly dividends. The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the contractual term of the option and similar instruments. · Risk-free rate(s). The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the contractual term of the option and similar instruments.
Income Tax, Policy [Policy Text Block]	Income Tax Provision The Company uses the asset and liability method of accounting for deferred income taxes. Deferred income taxes are measured by applying enacted statutory rates to net operating loss carryforwards and to the differences between the financial reporting and tax bases of assets and liabilities. Deferred tax assets are reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company recognizes uncertainty in income taxes in the financial statements using a recognition threshold and measurement attribute of a tax position taken or expected to be taken in a tax return. The Company applies the “more-likely-than-not” recognition threshold to all tax positions, commencing at the adoption date of the applicable accounting guidance, which resulted in no unrecognized tax benefits as of such date. Additionally, there have been no unrecognized tax benefits subsequent to adoption. The Company has opted to classify interest and penalties that would accrue, if any, according to the provisions of relevant tax law as selling, general, and administrative expenses, in the consolidated statement of operations. For the years ended June 30, 2015, 2014 and 2013 there was no such interest or penalty.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of Risk Financial instruments that potentially subject us to a significant concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured institutions in excess of federally insured limits. The Company does not believe it is exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15 is intended to define management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. Specifically, ASU 2014-15 provides a definition of the term substantial doubt and requires an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). It also requires certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans and requires an express statement and other disclosures when substantial doubt is not alleviated. The new standard will be effective for reporting periods beginning after December 15, 2016, with early adoption permitted. Management is currently evaluating the impact of the adoption of ASU 2014-15 on the Company’s financial statements and disclosures. In April 2015, the FASB issued ASU 2015-03, Interest - Imputation of Interest (Subtopic 835-30), “Simplifying the Presentation of Debt Issuance Costs,” which requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. This ASU requires retrospective adoption and will be effective for fiscal years beginning after December 15, 2015 and for interim periods within those fiscal years. We expect the adoption of this guidance will not have a material impact on our financial statements.

Summary of Significant Accoun21

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Potentially Outstanding Dilutive Common Shares For the For the Year Year Ended Ended June 30, 2015 June 30, 2014 Stock options 535,715 535,715 Warrants 5,976,675 8,887,211 Total potentially outstanding dilutive common shares 6,512,390 9,422,926 The following represents a reconciliation of the numerators and denominators of the basic and diluted per share calculations for income from continuing operations: For the Years Ended June 30, June 30, June 30, Calculation of basic loss per share of common stock: Net loss attributable to common stockholders $ (2,198,172) $ (13,601,616) $ (8,875,668) Denominator for basic weighted average shares of common stock 56,553,848 51,225,622 45,892,549 Basic loss per share of common stock $ (0.04) $ (0.27) $ (0.19) Calculation of diluted loss per share of common stock: Net loss attributable to common stockholders $ (2,198,172) $ (13,601,616) $ (8,875,668) Add: Loss impact of assumed conversion of Debentures (3,077,864) - (334,832) Net loss attributable to common stockholders plus assumed conversions $ (5,276,036) $ (13,601,616) $ (9,210,500) Denominator for basic weighted average shares of common stock 56,553,848 51,225,622 45,892,549 Incremental shares from assumed conversions of Debentures payable 2,666,667 - 1,714,286 Denominator for diluted weighted average shares of common stock 59,220,515 51,225,622 47,606,835 Diluted loss per share of common stock $ (0.09) $ (0.27) $ (0.19)

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Jun. 30, 2015
Related Party Transactions [Abstract]
Schedule of Related Party Transactions [Table Text Block]	For the Years Ended June 30, June 30, During the reporting period, the Company acquired 1 Controls Drive Shelton Ct from Inno-Haven, LLC $ 4,222,549 $ - During the reporting period, Inno-Haven, LLC, acquired property and equipment on behalf of the Company from third party vendors and sold such property and equipment, at cost, to the Company $ - $ 4,500,000 During the reporting period, TheraCour Pharma, Inc. acquired property and equipment on behalf of the Company from third party vendors and sold such property and equipment, at cost, to the Company $ 255,019 $ 528,720 Accounts Payable Related Party June 30, June 30, Pursuant to an Exclusive License Agreement and an Additional License Agreement we entered into with TheraCour Pharma, Inc., (TheraCour), the Company was granted exclusive licenses in perpetuity for technologies developed by TheraCour for the virus types: HIV, HCV, Herpes, Asian (bird) flu, Influenza and rabies, and others. In consideration for obtaining these exclusive licenses, we agreed: (1) that TheraCour can charge its costs (direct and indirect) plus no more than 30% of direct costs as a Development Fee and such development fees shall be due and payable in periodic installments as billed. (2) we will pay $25,000 per month for usage of lab supplies and chemicals from existing stock held by TheraCour, (3) we will pay $2,000 per month or actual costs, whichever is higher for other general and administrative expenses incurred by TheraCour on our behalf. Accounts payable due TheraCour Pharma Inc. (including a two (2) month security advance): $ 316,196 $ 49,455 Research and Development Costs Paid to Related Parties For the Year ended June 30, June 30, June 30, Development fees and other costs charged by and paid to TheraCour Pharma, Inc. pursuant to exclusive License Agreements between TheraCour and the Company for the development of the Company’s drug pipeline. No royalties are due TheraCour from the Company at June 30, 2015, 2014 and 2013 $ 2,403,126 $ 2,611,754 $ 1,988,046 Long Term Debenture Payable to a Director June 30, June 30, Series B Convertible Debentures - Milton Boniuk $ 4,000,000 $ 4,000,000 Series C Convertible Debentures - Milton Boniuk 5,000,000 - Total Long Term Debentures Payable to a Director $ 9,000,000 $ 4,000,000 Debenture Interest Paid to a Director June 30, June 30, Debenture interest was paid or recognized to Milton Boniuk, or an entity controlled by him, pursuant to the terms of the Series B and Series C Convertible Debentures. Coupon interest payable on $5,000,000 Series C Convertible Debentures and deferred. The deferred interest will be paid out quarterly over the remaining term of the debenture: Deferred interest payable - short term $ 166,667 $ - Deferred interest payable - long term $ 333,333 $ -

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Jun. 30, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment, stated at cost, less accumulated depreciation consisted of the following: June 30, June 30, Land $ 260,000 $ - Building GMP Facility 7,905,938 3,099,780 Office Equipment 65,241 30,048 Furniture and Fixtures 1,400 1,400 Lab Equipment & fixtures 5,264,272 3,605,514 Total Property and Equipment 13,496,851 6,736,742 Less Accumulated Depreciation (1,534,203) (1,239,986) Property and Equipment, Net $ 11,962,648 $ 5,496,756

Trademark and Patents (Tables)

Trademark and Patents (Tables)	12 Months Ended
	Jun. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets [Table Text Block]	Trademark and patents, stated at cost, less accumulated amortization consisted of the following: June 30, June 30, Trademarks and Patents $ 458,954 $ 458,954 Less Accumulated Amortization (59,217) (50,696) Trademarks and Patents, Net $ 399,737 $ 408,258
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Amortization expense in future years is as follows: 2016 $ 8,521 2017 8,521 2018 8,521 2019 8,521 2020 8,521 Thereafter 357,132 Total amortization $ 399,737

Convertible Debentures and In25

Convertible Debentures and Investor Warrants (Tables)	12 Months Ended
	Jun. 30, 2015
Series B Debentures [Member]
Schedule of Long-term Debt Instruments [Table Text Block]	The following table presents the balance of the Debenture payable – Series B, net of discount at June 30, 2015 and June 30, 2014. The debt discount is being accreted to interest expense over the term of the debenture: June 30, June 30, Proceeds $ 6,000,000 $ 6,000,000 Debt discount for bifurcated derivative (2,735,310) (2,735,310) 3,264,690 3,264,690 Amortization of debt discount 1,435,892 772,878 Debenture payable - Series B, net $ 4,700,582 $ 4,037,568
Series C Debentures [Member]
Schedule of Long-term Debt Instruments [Table Text Block]	The following represents the balance of the Debenture payable – Series C, net of discount at June 30, 2015: Proceeds $ 5,000,000 Debt discount Series A Preferred (1,152,297) Embedded derivative (1,879,428) 1,968,275 Amortization of debt discount for the year ended June 30, 2015 512,330 Balance at June 30, 2015 $ 2,480,605

Equity Transactions (Tables)

Equity Transactions (Tables)	12 Months Ended
	Jun. 30, 2015
Schedule of Stockholders Equity [Table Text Block]	The Company estimated the fair value of the warrants granted quarterly to the Scientific Advisory Board on the date of grant using the Black-Scholes Option-Pricing Model with the following weighted-average assumptions: June 30, Expected life (year) 4 Expected volatility 78.39%-98.09 % Expected annual rate of quarterly dividends 0.00 % Risk-free rate(s) .37-1.12 %
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	For the year ended June 30, 2015, the Company estimated the fair value of the warrants granted quarterly to the Scientific Advisory Board on the date of grant using the Black-Scholes Option-Pricing Model with the following weighted-average assumptions: Expected life (year) 4 Expected volatility 37.44% -45.84 % Expected annual rate of quarterly dividends 0.00 % Risk-free rate(s) 1.20 - 1.67 %
Series A Preferred Stock [Member]
Schedule Of Fair Value Of Stock Classified By Issuance Date [Table Text Block]	The fair value of the Series A Preferred stock at each date of issuance was as follows: Date Shares Value 7/31/2014 2,572 $ 25,821 8/31/2014 2,572 27,560 9/30/2014 2,572 19,602 10/31/2014 2,572 18,765 11/30/2014 2,572 22,025 12/31/2014 2,572 18,849 1/31/2015 2,572 16,501 2/28/2015 2,572 15,943 3/31/2015 2,572 16,299 4/30/2015 2,572 14,124 5/31/2015 2,572 11,460 6/30/2015 172,216 645,811 200,508 $ 852,760

Stock Options and Warrants (Tab

Stock Options and Warrants (Tables)	12 Months Ended
	Jun. 30, 2015
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The following table presents the activity of stock options issued for the period ended June 30, 2015 as follows: Stock Options Number of Weighted Weighted Aggregate Outstanding at June 30, 2013 535,715 0.35 2.23 1,521,429 Granted - - - - Exercised - - - - Expired - - - - Canceled - - - - Outstanding at June 30, 2014 535,715 $ 0.35 1.23 $ 2,094,643 Granted - - - - Exercised - - - - Expired - - - - Canceled - - - - Outstanding at June 30, 2015 535,715 $ 0.35 0.23 $ 749,997
Stock Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	As of June 30, 2015 there was no unrecognized compensation cost. Stock Warrants Number of Weighted Weighted Aggregate Outstanding at June 30, 2013 3,400,559 4.025 0.86 134,559 Granted 5,629,152 5.63 4.37 - Exercised 142,500 3.50 - - Expired - - - - Canceled - - - - Outstanding and exercisable at June 30, 2014 8,887,211 $ 5.01 2.78 $ 2,278,458 Granted 68,592 3.63 - - Exercised 1,926,656 3.50 - - Expired 1,052,472 3.50 - - Canceled - - - - Outstanding and exercisable at June 30, 2015 5,976,675 $ 5.14 3.20 $ 19,000

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	12 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]	At June 30, 2015 and 2014, the estimated fair values of the liabilities measured on a recurring basis are as follows: Fair Value Measurements at June 30, 2015: (Level 1) (Level 2) (Level 3) Derivative liability – Series B debentures $ - - $ 366,764 Derivative liability – Series C debentures - - 476,289 Derivative liability – warrants - - 3,442,754 Total derivatives $ - $ - $ 4,285,808 Fair Value Measurements at June 30, 2014: (Level 1) (Level 2) (Level 3) Derivative liability – Series B debentures $ - $ - 5,699,703 Derivative liability - warrants - - 5,235,682 Total derivatives $ - $ - $ 10,935,385
Schedule Of Projected Annual Volatility [Table Text Block]	The projected annual volatility for the valuation dates are: 1 Year 9/12/13 87 % 1/24/14 93 % 6/30/14 92 % 6/30/15 62 %
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following tables present the activity for liabilities measured at estimated fair value using unobservable inputs for the year ended June 30, 2015: Fair Value Measurement Unobservable Inputs Derivative Derivative Derivative Beginning balance at July 1, 2013 $ 3,751,645 $ - $ - Additions during the year - - 5,740,540 Change in fair value 1,948,058 - (504,858) Transfer in and/or out of Level 3 - - - Balance at July 1, 2014 $ 5,699,703 $ - $ 5,235,682 Additions during the year - 1,879,428 - Change in fair value (5,332,938) (1,403,139) (1,792,928) Transfer in and/or out of Level 3 - - - Balance at June 30, 2015 $ 366,765 $ 476,289 $ 3,442,754

Income Tax Provision (Tables)

Income Tax Provision (Tables)	12 Months Ended
	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	The income tax expense for the years ended June 30, 2015 and 2014 differed from the amounts computed by applying the U.S. federal income tax rate of 34% as follows: 6.30.2015 6.30.2014 Federal Statutory Rate -34.00 % -34.00 % Permanent Differences -37.00 % -37.00 % Valuation Allowance 71.00 % 71.00 % Effective Tax Rate 0.00 % 0.00 %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	The significant components of the Company’s deferred tax assets and liabilities at June 30, 2015 and 2014 are as follows: 6.30.2015 6.30.2014 Net operating losses 16,394,801 13,408,064 Research and Development Credit 4,800,186 3,422,745 Other 5,214,064 4,178,211 Total gross deferred tax assets 26,409,051 21,009,020 Less Valuation allowance (26,409,051) (21,009,020) Net deferred tax assets - -

Organization and Nature of Bu30

Organization and Nature of Business (Details Textual) - USD ($)	Sep. 12, 2013	Sep. 10, 2013	Feb. 15, 2010	Jun. 30, 2015	Jun. 30, 2014
Product Information [Line Items]
Entity Incorporation, State Country Name				Colorado
Entity Incorporation, Date Of Incorporation				Jul. 25, 2000
Business Acquisition, Name of Acquired Entity				Edot-com.com, Inc.
Business Acquisition, Date of Acquisition Agreement				May 12, 2005
Stock Issued During Period, Shares, New Issues	2,945,428
Common stock, shares issued				57,242,070	54,620,993
Common stock, shares, outstanding				57,242,070	54,620,993
Stockholders Equity, Reverse Stock Split		1 for 3.5
ECMM [Member]
Product Information [Line Items]
Common Stock Shares Issued Prorata Basis				4,000
Stock Issued During Period, Shares, New Issues				80,000,000
Common stock, shares issued				35,000,000
Common stock, shares, outstanding				35
Business Acquisition, Percentage of Voting Interests Acquired				80.00%
Series A Preferred Stock [Member]
Product Information [Line Items]
Preferred stock, shares issued			2,000,000
Preferred stock			$ 2,000
Convertible Preferred Stock, Terms of Conversion				The Series A Preferred Stock is convertible, only upon sale or merger of the Company, or the sale of or license of substantially all of the Companys intellectual property, into shares of the Companys common stock at the rate of 3.5 shares of common stock for each share of Series A Preferred Stock.
Stockholders Equity, Reverse Stock Split			(adjusted for the 3.5 to 1 reverse split)

Summary of Significant Accoun31

Summary of Significant Accounting Policies (Details) - shares	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,512,390	9,422,926
Stock options [Member]
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	535,715	535,715
Warrants [Member]
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	5,976,675	8,887,211

Summary of Significant Accoun32

Summary of Significant Accounting Policies (Details 1) - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Calculation of basic loss per share of common stock:
Net loss attributable to common stockholders	$ (2,198,172)	$ (13,601,616)	$ (8,875,668)
Denominator for basic weighted average shares of common stock	56,553,848	51,225,622	45,892,549
Basic loss per share of common stock	$ (0.04)	$ (0.27)	$ (0.19)
Calculation of diluted loss per share of common stock:
Net loss attributable to common stockholders	$ (2,198,172)	$ (13,601,616)	$ (8,875,668)
Add: Loss impact of assumed conversion of Debentures	(3,077,864)	0	(334,832)
Net loss attributable to common stockholders plus assumed conversions	$ (5,276,036)	$ (13,601,616)	$ (9,210,500)
Denominator for basic weighted average shares of common stock	56,553,848	51,225,622	45,892,549
Incremental shares from assumed conversions of Debentures payable	2,666,667	0	1,714,286
Denominator for diluted weighted average shares of common stock	59,220,515	51,225,622	47,606,835
Diluted loss per share of common stock	$ (0.09)	$ (0.27)	$ (0.19)

Summary of Significant Accoun33

Summary of Significant Accounting Policies (Details Textual) - Range [Domain] - Antidilutive Securities, Name [Domain] - $ / shares	12 Months Ended
	Jun. 30, 2015	Jan. 15, 2016	Jun. 30, 2014	Feb. 06, 2014	Sep. 09, 2013
Accounting Policies [Line Items]
Common Stock, Par Or Stated Value Per Share	$ 0.001		$ 0.001	$ 0.001	$ 0.001
Debt Instrument, Redemption, Description	the Company, at its sole option, shall have the right, but not the obligation, to repurchase the Debenture at any time prior to the Maturity Date (the Redemption). If the Company intends to repurchase the Debenture, and if the closing bid price of the Common Stock is greater than $5.25 on the Redemption Date, unless the Holder, on or prior to the Redemption Date, elects to receive the Redemption Payment, as that term is defined herein, the Company shall pay to the Holder: (i) 952,381 shares of Common Stock in consideration of the exchange of the principal amount of the Debenture; and (ii) any and all accrued coupon interest. If on or prior to the Redemption Date, the Holder elects to receive the Redemption Payment, or the closing bid price of the Common Stock is less than $5.25, the Company shall issue to the Holder: (i) the principal amount of the Debenture; (ii) any accrued coupon interest; (iii) additional interest of 7% per annum for the period from the date of issuance of the Debenture to the Redemption Date; and (iv) warrants to purchase 619,048 shares of Common Stock which shall expire in three years from the date of issuance at an exercise price of $6.05 per share of Common Stock (the Redemption Warrants, and collectively with (i) (iii), the Redemption Payment). The Company shall use its best efforts to register the shares underlying the Redemption Warrants under a shelf registration statement, provided same is available to the Company, in accordance with the provisions of the Securities Act.
Building [Member]
Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life	30 years
Land Improvements [Member]
Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life	15 years
Equipment [Member]
Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Office Equipment [Member]
Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Scenario, Forecast [Member]
Accounting Policies [Line Items]
Common Stock, Par Or Stated Value Per Share		$ 0.001
Convertible Debentures Shares Reserved For Future issuance		571,428
Series A Convertible Preferred Stock [Member]
Accounting Policies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 3.5
Convertible Preferred Stock, Shares Issued upon Conversion	12,542,058
Preferred Stock, Shares Issued	3,583,445		3,193,079
Preferred Stock, Par Value (In Dollars Per Share)	$ 0.001		$ 0.001
Common Stock [Member] | Series B Convertible Debentures [Member]
Accounting Policies [Line Items]
Debt Conversion, Converted Instrument, Shares Issued	1,714,286
Debt Instrument, Convertible, Conversion Price	$ 3.50
Common Stock [Member] | Series C Convertible Debentures [Member]
Accounting Policies [Line Items]
Debt Conversion, Converted Instrument, Shares Issued	952,381

Financial Condition (Details Te

Financial Condition (Details Textual) - USD ($)	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Financial Condition [Line Items]
Cash and cash equivalents	$ 31,467,748	$ 36,696,892	$ 13,923,245	$ 14,274,985
Retained Earnings (Accumulated Deficit)	$ (54,099,572)	$ (51,901,400)

Related Party Transactions (Det

Related Party Transactions (Details) - Class Of Stock [Domain] - Derivative, Name [Domain] - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Research and development	$ 3,660,322	$ 5,131,523	$ 4,292,909
Due to Related Parties	9,000,000	4,000,000
Deferred interest payable - short term	166,667	0
Deferred interest payable - long term	333,333	0
Series B Convertible Debentures [Member]
Due to Related Parties	4,000,000	4,000,000
Series C Convertible Debenture [Member]
Due to Related Parties	5,000,000	0
Deferred interest payable - short term	166,667	0
Deferred interest payable - long term	333,333	0
Innohaven, LLC [Member] | Option One [Member]
Due to Related Parties	4,222,549	0
Innohaven, LLC [Member] | Option Two [Member]
Due to Related Parties	0	4,500,000
TheraCour Pharma, Inc [Member]
Net Account Payable to related party	316,196	49,455
Research and development	2,403,126	2,611,754	$ 1,988,046
Due to Related Parties	$ 255,019	$ 528,720

Related Party Transactions (D36

Related Party Transactions (Details Textual) - Entity [Domain] - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Related Party Transaction [Line Items]
Related Party Transaction, Description of Transaction	charge its costs (direct and indirect) plus no more than 30% of direct costs
Lab Supplies and Chemicals Fees	$ 25,000
Other General and Administrative Expense	2,000
Due to Related Parties	9,000,000	$ 4,000,000
Debenture Interest Paid [Member]
Related Party Transaction [Line Items]
Due to Related Parties	320,000	320,000	$ 197,589
Series B Convertible Debenture [Member]
Related Party Transaction [Line Items]
Debt Instrument, Face Amount	$ 4,000,000
Weighted Average Discount Rate, Percent	21.60%
Due to Related Parties		$ 1,730,763	$ 665,497
Series C Convertible Debenture [Member]
Related Party Transaction [Line Items]
Debt Instrument, Face Amount	$ 5,000,000
Interest Payable	$ 5,000,000

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	Jun. 30, 2015	Jun. 30, 2014
Property, Plant and Equipment [Line Items]
Land	$ 260,000	$ 0
Building GMP Facility	7,905,938	3,099,780
Office Equipment	65,241	30,048
Furniture and Fixtures	1,400	1,400
Lab Equipment & fixtures	5,264,272	3,605,514
Total Property and Equipment	13,496,851	6,736,742
Less Accumulated Depreciation	(1,534,203)	(1,239,986)
Property and Equipment, Net	$ 11,962,648	$ 5,496,756

Property and Equipment (Detai38

Property and Equipment (Details Textual) - USD ($)	1 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2014	Mar. 31, 2014	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Property, Plant and Equipment [Line Items]
Depreciation		$ 203,234	$ 294,217	$ 203,234	$ 210,877
Acquisition and Renovation Expenses of Manufacturing and Lab Facility	$ 4,222,549
Closing Costs Of Facility	$ 81,230

Trademark and Patents (Details)

Trademark and Patents (Details) - USD ($)	Jun. 30, 2015	Jun. 30, 2014
Trademarks And Patents [Line Items]
Trademarks and Patents	$ 458,954	$ 458,954
Less Accumulated Amortization	(59,217)	(50,696)
Trademarks and Patents, Net	$ 399,737	$ 408,258

Trademark and Patents (Details

Trademark and Patents (Details 1) - USD ($)	Jun. 30, 2015	Jun. 30, 2014
Finite-Lived Intangible Assets [Line Items]
2,016	$ 8,521
2,017	8,521
2,018	8,521
2,019	8,521
2,020	8,521
Thereafter	357,132
Total amortization	$ 399,737	$ 408,258

Trademark and Patents (Detail41

Trademark and Patents (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Trademarks And Patents [Line Items]
Amortization	$ 8,521	$ 8,775	$ 8,774
Trademark and Patents [Member]
Trademarks And Patents [Line Items]
Amortization	$ 8,521	$ 8,775	$ 8,774
Finite-Lived Intangible Asset, Useful Life	17 years

Convertible Debentures and In42

Convertible Debentures and Investor Warrants (Details) - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Debenture payable - Series B, net	$ 0	$ 5,000,000
Series B Debentures [Member]
Proceeds	6,000,000	6,000,000
Debt discount for bifurcated derivative	(2,735,310)	(2,735,310)
Net Proceeds From Issuance Of Debt	3,264,690	3,264,690
Amortization of debt discount	1,435,892	772,878
Debenture payable - Series B, net	$ 4,700,582	$ 4,037,568

Convertible Debentures and In43

Convertible Debentures and Investor Warrants (Details 1) - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Balance at December 31, 2014	$ 0	$ 5,000,000
Series C Debentures [Member]
Proceeds	5,000,000
Debt discount	(1,879,428)
Net Proceeds From Issuance Of Debt	1,968,275
Amortization of debt discount	512,330
Balance at December 31, 2014	2,480,605
Series A Preferred Stock [Member] | Series C Debentures [Member]
Debt discount	$ (1,152,297)

Convertible Debentures and In44

Convertible Debentures and Investor Warrants (Details Textual) - USD ($)	Jul. 02, 2014	Feb. 28, 2013	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013	Jul. 17, 2014	Feb. 06, 2014	Jan. 24, 2014	Sep. 09, 2013	Feb. 02, 2013
Debt Instrument [Line Items]
Common stock, par value (in dollars per share)			$ 0.001	$ 0.001			$ 0.001		$ 0.001
Proceeds From Convertible Debt				$ 5,000,000	$ 6,000,000
Debt Conversion, Converted Instrument, Amount			$ 1,152,297	0	0
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 3.50		$ 6.05	$ 5.25
Debt Instrument, Redemption, Description			the Company, at its sole option, shall have the right, but not the obligation, to repurchase the Debenture at any time prior to the Maturity Date (the Redemption). If the Company intends to repurchase the Debenture, and if the closing bid price of the Common Stock is greater than $5.25 on the Redemption Date, unless the Holder, on or prior to the Redemption Date, elects to receive the Redemption Payment, as that term is defined herein, the Company shall pay to the Holder: (i) 952,381 shares of Common Stock in consideration of the exchange of the principal amount of the Debenture; and (ii) any and all accrued coupon interest. If on or prior to the Redemption Date, the Holder elects to receive the Redemption Payment, or the closing bid price of the Common Stock is less than $5.25, the Company shall issue to the Holder: (i) the principal amount of the Debenture; (ii) any accrued coupon interest; (iii) additional interest of 7% per annum for the period from the date of issuance of the Debenture to the Redemption Date; and (iv) warrants to purchase 619,048 shares of Common Stock which shall expire in three years from the date of issuance at an exercise price of $6.05 per share of Common Stock (the Redemption Warrants, and collectively with (i) (iii), the Redemption Payment). The Company shall use its best efforts to register the shares underlying the Redemption Warrants under a shelf registration statement, provided same is available to the Company, in accordance with the provisions of the Securities Act.
Long-term Debt, Excluding Current Maturities, Total			$ 0	$ 5,000,000
Maximum [Member]
Debt Instrument [Line Items]
Projected Redemption Percentage Of Time				20.00%
Restricted Stock [Member]
Debt Instrument [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance										571,429
Warrant [Member]
Debt Instrument [Line Items]
Investment Warrants, Exercise Price			$ 3.50
Debt Instrument, Term			3 years
Derivative Liability, Noncurrent			$ 3,442,754	$ 5,235,682
Series B Convertible Debentures [Member]
Debt Instrument [Line Items]
Amortization of Debt Discount (Premium)			663,014	569,495	$ 203,383
Proceeds From Convertible Debt			$ 6,000,000	$ 6,000,000
Debt Instrument, Term			4 years
Debt Instrument, Interest Rate, Stated Percentage				8.00%
Warrants To Be Issued In Fourth Year										571,429
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 3.50	$ 3.50						$ 3.50
Debt Instrument, Redemption, Description		The Company can prepay the debentures, in which case the base interest rate shall increase by a 7% prepayment penalty. The Company agreed to use its best efforts to register the interest shares and the shares issuable from the interest warrants under a shelf registration statement provided same is available, in accordance with the provisions of the Securities Act
Long-term Debt, Excluding Current Maturities, Total			$ 6,000,000
Share Price			$ 1.75	$ 4.23
Debt Instrument, Debt Default, Description of Violation or Event of Default			An event of default would occur 0% of the time, increasing 1.00% per month to a maximum of 10%	An event of default would occur 0% of the time, increasing 1.00% per month to a maximum of 10%
Derivative Liability, Noncurrent			$ 366,764	$ 5,699,703
Projected Redemption Percentage Of Time			0.00%	0.00%
Projected Annual Volatility Percentage			62.00%	92.00%
Weighted Average Discount Rate, Percent			21.60%	21.60%
Series B Convertible Debentures [Member] | Maximum [Member]
Debt Instrument [Line Items]
Projected Redemption Percentage Of Time			20.00%	20.00%
Series B Convertible Debentures [Member] | Minimum [Member]
Debt Instrument [Line Items]
Projected Redemption Percentage Of Time			1.00%	1.00%
Series B Convertible Debentures [Member] | Director [Member]
Debt Instrument [Line Items]
Proceeds From Convertible Debt			$ 4,000,000
Series A Convertible Preferred Stock [Member]
Debt Instrument [Line Items]
Amortization of Debt Discount (Premium)			$ 512,330
Debt Conversion, Converted Instrument, Shares Issued	187,000
Proceeds From Convertible Debt	$ 1,645,606
Repayments of Other Debt	1,152,297
Debt Instrument, Unamortized Discount	1,152,297
Debt Conversion, Converted Instrument, Amount	$ 1,879,428
Series C Convertible Preferred Stock [Member]
Debt Instrument [Line Items]
Common stock, par value (in dollars per share)	$ 0.001
Debt Instrument, Convertible, Conversion Price	$ 5.25
Debt Instrument, Convertible, Carrying Amount of Equity Component	$ 5,000,000
Redemption On Debentures	952,381
Warrants to purchase of Common Stock	619,048
Common stock exercise price	$ 6.05
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 5.25
Projected Annual Volatility Percentage	92.00%		62.00%
Series C Convertible Preferred Stock [Member] | Maximum [Member]
Debt Instrument [Line Items]
Projected Redemption Percentage Of Time				5.00%
Series C Convertible Debenture [Member]
Debt Instrument [Line Items]
Debt Instrument, Maturity Date			Jun. 30, 2018
Proceeds from Issuance of Debt	$ 5,000,000
Debt Instrument, Interest Rate, Stated Percentage	10.00%
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 5.25
Long-term Debt, Excluding Current Maturities, Total	$ 5,000,000		$ 5,000,000
Share Price	$ 3		$ 1.75
Debt Instrument, Debt Default, Description of Violation or Event of Default	An event of default would occur 0% of the time, increasing 1.00% per month to a maximum of 10%		An event of default would occur 0% of the time, increasing 1.00% per month to a maximum of 10%
Derivative Liability, Noncurrent			$ 476,289
Projected Redemption Percentage Of Time	0.00%		0.00%
Weighted Average Discount Rate, Percent			21.97%	21.86%
Closing Common Stock Bid Price	$ 5.25
Additional Interest Rate For Warrants	7.00%
Payments of Derivative Issuance Costs			$ 1,879,428
Series C Convertible Debenture [Member] | Maximum [Member]
Debt Instrument [Line Items]
Projected Redemption Percentage Of Time	5.00%		5.00%
Series C Convertible Debenture [Member] | Minimum [Member]
Debt Instrument [Line Items]
Projected Redemption Percentage Of Time	1.00%		1.00%

Equity Transactions (Details)

Equity Transactions (Details)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Class of Stock [Line Items]
Expected life (year)	4 years	4 years
Expected annual rate of quarterly dividends	0.00%	0.00%
Maximum [Member]
Class of Stock [Line Items]
Expected volatility		98.09%
Risk-free rate(s)		1.12%
Minimum [Member]
Class of Stock [Line Items]
Expected volatility		78.39%
Risk-free rate(s)		0.37%

Equity Transactions (Details 1)

Equity Transactions (Details 1)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	4 years	4 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum	37.44%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum	45.84%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum	1.20%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum	1.67%

Equity Transactions (Details 2)

Equity Transactions (Details 2) - 12 months ended Jun. 30, 2015 - Series A Preferred Stock [Member] - USD ($)	Total
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross	200,508
Stock Issued During Period, Value, Share-based Compensation, Gross	$ 852,760
7/31/2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross	2,572
Stock Issued During Period, Value, Share-based Compensation, Gross	$ 25,821
8/31/2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross	2,572
Stock Issued During Period, Value, Share-based Compensation, Gross	$ 27,560
9/30/2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross	2,572
Stock Issued During Period, Value, Share-based Compensation, Gross	$ 19,602
10/31/2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross	2,572
Stock Issued During Period, Value, Share-based Compensation, Gross	$ 18,765
11/30/2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross	2,572
Stock Issued During Period, Value, Share-based Compensation, Gross	$ 22,025
12/31/2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross	2,572
Stock Issued During Period, Value, Share-based Compensation, Gross	$ 18,849
1/31/2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross	2,572
Stock Issued During Period, Value, Share-based Compensation, Gross	$ 16,501
2/28/2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross	2,572
Stock Issued During Period, Value, Share-based Compensation, Gross	$ 15,943
3/31/2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross	2,572
Stock Issued During Period, Value, Share-based Compensation, Gross	$ 16,299
4/30/2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross	2,572
Stock Issued During Period, Value, Share-based Compensation, Gross	$ 14,124
5/31/2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross	2,572
Stock Issued During Period, Value, Share-based Compensation, Gross	$ 11,460
6/30/2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross	172,216
Stock Issued During Period, Value, Share-based Compensation, Gross	$ 645,811

Equity Transactions (Details Te

Equity Transactions (Details Textual)	Jul. 02, 2014USD ($)shares	Feb. 06, 2014USD ($)$ / sharesshares	Sep. 12, 2013USD ($)shares	Sep. 10, 2013	Sep. 09, 2013USD ($)$ / shares	Jan. 24, 2015USD ($)shares	Jul. 17, 2014USD ($)$ / sharesshares	Jan. 31, 2014	Jan. 21, 2014USD ($)$ / sharesshares	Dec. 30, 2013$ / sharesshares	Sep. 25, 2013USD ($)$ / sharesshares	Jun. 30, 2013shares	Jun. 30, 2015USD ($)$ / sharesshares	Jun. 30, 2014USD ($)$ / sharesshares	Jun. 30, 2013USD ($)$ / sharesshares	Feb. 01, 2015USD ($)$ / sharesshares	Jan. 24, 2014$ / shares
Class of Stock [Line Items]
Purchase Price Per Share | $ / shares					$ 3.50
Proceeds from Issuance Initial Public Offering | $		$ 131,750	$ 10,308,996			$ 20,030,207			$ 393,750
Placement Agents and Attorneys Fees | $			$ 618,540			$ 1,200,000
Stockholders Equity, Reverse Stock Split				1 for 3.5
Common stock, par value (in dollars per share) | $ / shares		$ 0.001			0.001								$ 0.001	$ 0.001
Stock Issued During Period Price Per Share One | $ / shares									$ 5.25	$ 3.50					$ 0.001
Conversion of Stock, Description													i) the converted value to common at a ratio of 1:3.5
Number Of Common Stock To Be Issued Upon Conversion Of Warrants		25,000							75,000	7,143			68,592		71,428
Stock Issued During Period Price Per Share | $ / shares					$ 5.25
Fair Value Of Common Stock Warrant Issued During Period For Consulting Services | $					$ 113,696								$ 59,675
Common Stock Issued During Period Settlement Of Accounts Payable Value | $															$ 60,000
Warrants Exercise Price | $ / shares									$ 6.05
Stock Issued During Period, Shares, New Issues			2,945,428
Description Of Offering					the Company paid the Placement Agents an aggregate cash fee representing 6% (3% each) of the gross Purchase Price paid by the Purchasers and warrants to purchase an aggregate of 2% (1% each) of the number of shares of Common Stock sold in the Offering (the Compensation Warrants) and substantially similar to the Warrants, at an exercise price equal to $5.25 per share.			the Placement Agents an aggregate cash fee representing 6% of the gross Purchase Price paid by the Purchasers and warrants to purchase an aggregate of 2% of the number of shares of Common Stock sold in the Offering (the Compensation Warrants) representing two percent of the Shares and substantially similar to the Warrants, at an exercise price equal to $6.05 per share.
Adjustments to Additional Paid in Capital, Warrant Issued | $					$ 113,696
Purchase Price Per Unit Description									The price per Unit was equal to a four percent (4%) discount to the 20-day VWAP of the Companys stock price on Friday, January 17, 2014. The exercise price of the Warrant was equal to the closing price of the Companys stock on Friday, January 17, 2014. Each Unit consisted of one share of the Companys common stock, par value $0.001 per share (the Common Stock) and Sixty-Five Hundredths (65/100) of a warrant to purchase one share of Common Stock (Warrant),
Stockholders Equity Note, Stock Split, Conversion Ratio													3.5
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares					$ 5.25		$ 3.50										$ 6.05
Interest Payable, Current | $													$ 166,667	$ 0
Common Stock, Shares Authorized													150,000,000	85,714,286
Warrants Issued To Purchase Of Common Stock							1,926,656
Aggregate Purchase Price Of Warrants | $							$ 6,743,297
Common Stock, Shares, Outstanding													57,242,070	54,620,993
Minimum [Member]
Class of Stock [Line Items]
Stock Issued During Period Price Per Share | $ / shares													$ 2
Minimum [Member] | Fair Value Inputs [Member]
Class of Stock [Line Items]
Common Stock, Shares, Outstanding														47,026,173
Fair Value Inputs Total Voting Shares														54,506,459
Maximum [Member]
Class of Stock [Line Items]
Stock Issued During Period Price Per Share | $ / shares													$ 5.02
Maximum [Member] | Fair Value Inputs [Member]
Class of Stock [Line Items]
Common Stock, Shares, Outstanding														54,614,930
Fair Value Inputs Total Voting Shares														62,208,499
Warrant [Member]
Class of Stock [Line Items]
Proceeds from Issuance Initial Public Offering | $											$ 185,624
Common stock, par value (in dollars per share) | $ / shares					$ 0.001						$ 0.001
Number Of Common Stock To Be Issued Upon Conversion Of Warrants						2,479,935					35,357			72,439	68,572
Common Stock Issued During Period Settlement Of Accounts Payable Value | $														$ 199,849
Stock Issued During Period, Shares, New Issues						3,815,285
Fair Value Measurements, Significant Assumptions													a.The common stock price was in the range $2.29 to $1.55; b. The calculated weighted average number of shares of common stock in the period; c. A 5.36% premium over the common shares for the voting preferences; d. The calculated weighted average number of total voting shares and the monthly shares representing voting rights of 4.896% to 5.046% of the total; e. The conversion value is based on an assumption for calculation purposes only of a Change of Control in 4 years from March 1, 2013 and a remaining restricted term of 1.92 to 1.67 years; f. 30.86% to 31.42% restricted stock discount (based on a restricted stock analysis and call-put analysis curve: 63.52% to 69.38% volatility, 0. 22% to 0.26% risk free rate) applied to the converted common.	a. The common stock price (post-reverse split) was in the range $2.45 to $3.90; b. 47,026,173 to 54,614,930 shares outstanding and Series A Preferred shares with 2,572 (post–split 9/10/13) issued monthly ; and 169,644 issued annually to employees . c. A 5.36% premium over the common shares for the voting preferences; d. 54,506,459 to 62,208,499 total voting shares and the monthly shares representing voting rights of 0.042% to 0.484% of the total; and the annual shares representing 1.02% to 2.389% of the total; e. The conversion value is based on an assumption for calculation purposes only of a Change of Control in 4 years from 3/1/13 and a restricted term of 3.67 to 2.67 years; f. 42.87% to 27.11% restricted stock discount (based on a restricted stock analysis and call-put analysis curve: 121.97% to 265.70% volatility, 0.37% to 1.62% risk-free rate) applied to the converted common.
Common Stock, Shares Authorized							3,071,986
Preferred Series A shares [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross													71,430
Stock Issued During Period, Value, Share-based Compensation, Gross | $													$ 125,003
Director [Member]
Class of Stock [Line Items]
Shares issued to a Director for services rendered (in shares)															8,521
Stock Issued During Period, Value, Issued For Services | $															$ 18,750
Number Of Common Stock To Be Issued Upon Conversion Of Warrants														13,146
Common Stock Issued During Period Settlement Of Accounts Payable Value | $														$ 45,000
Stock Issued During Period, Shares, Share-based Compensation, Gross													16,408
Stock Issued During Period, Value, Share-based Compensation, Gross | $													$ 45,000
Consulting Services [Member]
Class of Stock [Line Items]
Shares issued to a Director for services rendered (in shares)												42,977
Stock Issued During Period, Value, Issued For Services | $															84,956
Number Of Common Stock To Be Issued Upon Conversion Of Warrants														29,662
Common Stock Issued During Period Settlement Of Accounts Payable Value | $														$ 102,001	$ 141,600
Stock Issued During Period, Shares, Share-based Compensation, Gross													35,154
Stock Issued During Period, Value, Share-based Compensation, Gross | $													$ 109,360
Employee Compensation [Member]
Class of Stock [Line Items]
Shares issued to a Director for services rendered (in shares)													200,508
Stock Issued During Period, Value, Issued For Services | $													$ 852,760	$ 287,860
Number Of Common Stock To Be Issued Upon Conversion Of Warrants														71,430
Stock Issued During Period Price Per Share | $ / shares														$ 0.001
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Value, Issued For Services | $														$ 2,123,014
Stock Issued During Period Price Per Share One | $ / shares															$ 0.001
Number Of Common Stock To Be Issued Upon Conversion Of Warrants														203,079	169,643
Stock Issued During Period Price Per Share | $ / shares														$ 0.001
Common Stock Issued During Period Settlement Of Accounts Payable Value | $															$ 445,044
Stock Issued During Period, Shares, Share-based Compensation, Gross													2,858
Stock Issued During Period, Value, Share-based Compensation, Gross | $													$ 24,474
Preferred Stock, Shares Issued													3,583,445	3,193,079
Preferred Shares Issued To Employees Fair Value Disclosure | $														$ 2,123,014
Series A Convertible Preferred Stock [Member] | Long-Term Debentures Payable [Member]
Class of Stock [Line Items]
Stock Issued During Period, Value, Issued For Services | $	$ 1,152,297
Debt Conversion, Converted Instrument, Shares Issued	187,000
Series A Convertible Preferred Stock [Member] | Minimum [Member] | Fair Value Inputs [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Issued														2,572
Series A Convertible Preferred Stock [Member] | Maximum [Member] | Fair Value Inputs [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Issued														169,644
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Value, Issued For Services | $														$ 2,605,716
Stock Issued During Period Price Per Share One | $ / shares														$ 0.001
Number Of Common Stock To Be Issued Upon Conversion Of Warrants														571,429
Preferred Stock, Shares Issued													0	0
Series B Debentures [Member]
Class of Stock [Line Items]
Common stock, par value (in dollars per share) | $ / shares																$ 0.001
Interest Payable, Current | $																$ 1,502,870
Board Of Directors Authorized Number Of Shares																571,433
Series B Convertible Debentures [Member]
Class of Stock [Line Items]
Stock Issued During Period Price Per Share | $ / shares															$ 0.001
Common Stock Issued During Period Settlement Of Accounts Payable Shares															571,429
Interest Expense, Debt | $															$ 665,497

Stock Options and Warrants (Det

Stock Options and Warrants (Details) - Stock Options [Member] - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding	535,715	535,715
Number of Shares, Granted	0	0
Number of Shares, Exercised	0	0
Number of Shares, Expired	0	0
Number of Shares, Canceled	0	0
Number of Shares, Outstanding	535,715	535,715	535,715
Weighted Average Exercise Price per share , Outstanding	$ 0.35	$ 0.35
Weighted Average Exercise Price per share, Granted	0	0
Weighted Average Exercise Price per share, Exercised	0	0
Weighted Average Exercise Price per share, Expired	0	0
Weighted Average Exercise Price per share, Canceled	0	0
Weighted Average Exercise Price per share , Outstanding	$ 0.35	$ 0.35	$ 0.35
Weighted Average Remaining Contractual Term, (years) Granted
Weighted Average Remaining Contractual Term, (years) Exercised
Weighted Average Remaining Contractual Term, (years) Expired
Weighted Average Remaining Contractual Term, (years) Canceled
Weighted Average Remaining Contractual Term, (years) Outstanding	2 months 23 days	1 year 2 months 23 days	2 years 2 months 23 days
Aggregate Intrinsic Value, Outstanding	$ 749,997	$ 2,094,643	$ 1,521,429
Aggregate Intrinsic Value, Granted	0	0
Aggregate Intrinsic Value, Exercised	0	0
Aggregate Intrinsic Value, Expired	0	0
Aggregate Intrinsic Value, Canceled	$ 0	$ 0

Stock Options and Warrants (D50

Stock Options and Warrants (Details 1) - Stock Warrants [Member] - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding	8,887,211	3,400,559
Number of Shares, Granted	68,592	5,629,152
Number of Shares, Exercised	1,926,656	142,500
Number of Shares, Expired	1,052,472	0
Number of Shares, Canceled	0	0
Number of Shares, Outstanding	5,976,675	8,887,211	3,400,559
Weighted Average Exercise Price per share , Outstanding	$ 5.01	$ 4.025
Weighted Average Exercise Price per share, Granted	3.63	5.63
Weighted Average Exercise Price per share, Exercised	3.50	3.50
Weighted Average Exercise Price per share, Expired	3.50	0
Weighted Average Exercise Price per share, Canceled	0	0
Weighted Average Exercise Price per share , Outstanding	$ 5.14	$ 5.01	$ 4.025
Weighted Average Remaining Contractual Term, (years) Granted		4 years 4 months 13 days
Weighted Average Remaining Contractual Term, (years) Exercised
Weighted Average Remaining Contractual Term, (years) Expired
Weighted Average Remaining Contractual Term, (years) Canceled
Weighted Average Remaining Contractual Term, (years) Outstanding	3 years 2 months 12 days	2 years 9 months 11 days	10 months 10 days
Aggregate Intrinsic Value, Outstanding	$ 19,000	$ 2,278,458	$ 134,559
Aggregate Intrinsic Value, Granted	0	0
Aggregate Intrinsic Value, Exercised	0	0
Aggregate Intrinsic Value, Expired	0	0
Aggregate Intrinsic Value, Cancelled	$ 0	$ 0

Stock Options and Warrants (D51

Stock Options and Warrants (Details Textual) - 12 months ended Jun. 30, 2015 - shares	Total
June 30, 2016 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	345,720
Warrants Expiration Date	Jun. 30, 2016
June 30, 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	68,571
Warrants Expiration Date	Jun. 30, 2017
June 30 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	68,570
Warrants Expiration Date	Jun. 30, 2018
June 30, 2019 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	5,493,814
Warrants Expiration Date	Jun. 30, 2019

Fair Value Measurement (Details

Fair Value Measurement (Details) - USD ($)	Jun. 30, 2015	Jun. 30, 2014
Warrant [Member]
Derivative Liability, Noncurrent	$ 3,442,754	$ 5,235,682
Fair Value, Inputs, Level 1 [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 1 [Member] | Derivative liability - Series B debentures [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 1 [Member] | Derivative liability - Series C debentures [Member]
Derivative Liability, Noncurrent	0
Fair Value, Inputs, Level 1 [Member] | Warrant [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 2 [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 2 [Member] | Derivative liability - Series B debentures [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 2 [Member] | Derivative liability - Series C debentures [Member]
Derivative Liability, Noncurrent	0
Fair Value, Inputs, Level 2 [Member] | Warrant [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 3 [Member]
Derivative Liability, Noncurrent	4,285,808	10,935,385
Fair Value, Inputs, Level 3 [Member] | Derivative liability - Series B debentures [Member]
Derivative Liability, Noncurrent	366,764	5,699,703
Fair Value, Inputs, Level 3 [Member] | Derivative liability - Series C debentures [Member]
Derivative Liability, Noncurrent	476,289
Fair Value, Inputs, Level 3 [Member] | Warrant [Member]
Derivative Liability, Noncurrent	$ 3,442,754	$ 5,235,682

Fair Value Measurement (Detai53

Fair Value Measurement (Details 1)	12 Months Ended
	Jun. 30, 2015
One year ended 9/12/2013
Fair Value Assumptions, Expected Volatility Rate	87.00%
One year ended 1/24/2014
Fair Value Assumptions, Expected Volatility Rate	93.00%
One year ended 6/30/2014
Fair Value Assumptions, Expected Volatility Rate	92.00%
One year ended 6/30/2015
Fair Value Assumptions, Expected Volatility Rate	62.00%

Fair Value Measurement (Detai54

Fair Value Measurement (Details 2) - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Warrant [Member]
Begining Balance	$ 5,235,682	$ 0
Additions during the year	0	5,740,540
Change in fair value	(1,792,928)	(504,858)
Transfer in and/or out of Level 3	0	0
Ending Balance	3,442,754	5,235,682
Derivative liability - Series C debentures [Member]
Begining Balance	0	0
Additions during the year	1,879,428	0
Change in fair value	(1,403,139)	0
Transfer in and/or out of Level 3	0	0
Ending Balance	476,289	0
Derivative liability - Series B debentures One [Member]
Begining Balance	5,699,703	3,751,645
Additions during the year	0	0
Change in fair value	(5,332,938)	1,948,058
Transfer in and/or out of Level 3	0	0
Ending Balance	$ 366,765	$ 5,699,703

Fair Value Measurement (Detai55

Fair Value Measurement (Details Textual) - $ / shares	Sep. 12, 2013	Sep. 10, 2013	Sep. 09, 2013	Jan. 24, 2014	Jun. 30, 2015	Jul. 17, 2014
Class of Warrant or Right, Outstanding		2,910,071		2,379,935
Warrants Issued	2,945,428			2,479,935
Warrant Expiration Term			5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 5.25	$ 6.05		$ 3.50
Placement Agents [Member]
Warrants Issued		58,910		76,306
Scientific Advisory Board [Member]
Warrants Issued					68,592

Income Tax Provision (Details)

Income Tax Provision (Details)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Income Tax Provision [Line Items]
Federal Statutory Rate	(34.00%)	(34.00%)
Permanent Differences	(37.00%)	(37.00%)
Valuation Allowance	71.00%	71.00%
Effective Tax Rate	0.00%	0.00%

Income Tax Provision (Details 1

Income Tax Provision (Details 1) - USD ($)	Jun. 30, 2015	Jun. 30, 2014
Income Tax Provision [Line Items]
Net operating losses	$ 16,394,801	$ 13,408,064
Research and Development Credit	4,800,186	3,422,745
Other	5,214,064	4,178,211
Total gross deferred tax assets	26,409,051	21,009,020
Less Valuation allowance	(26,409,051)	(21,009,020)
Net deferred tax assets	$ 0	$ 0

Income Tax Provision (Details T

Income Tax Provision (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Operating Loss Carryforwards, Expiration Date	Jun. 30, 2035
Deferred Tax Assets, Valuation Allowance	$ 26,409,051	$ 21,009,020
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	5,400,000
Operating Loss Carryforwards	43,400,000
Domestic Tax Authority [Member]
Operating Loss Carryforwards	4,177,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards	$ 623,000

Commitments and Contingencies (

Commitments and Contingencies (Details Textual) - Entity [Domain]	1 Months Ended				12 Months Ended
	Jan. 31, 2015USD ($)	May. 30, 2013USD ($)shares	Feb. 28, 2011USD ($)ft²	Mar. 31, 2010USD ($)shares	Jun. 30, 2015USD ($)shares	Jun. 30, 2014USD ($)shares	Jun. 30, 2013USD ($)
Commitments and Contingencies [Line Items]
Space For Office and Laboratory | ft²			7,000
Monthly Base Rent			$ 8,695
Lease Expiration Date			Feb. 28, 2011
Operating Leases, Rent Expense, Net					$ 104,340	$ 104,340	$ 102,030
Minimum Annual Base Salary				$ 250,000
Proceeds From Financing				$ 5,000,000
Employment Agreement Term				4 years
Common stock, shares issued | shares					57,242,070	54,620,993
Common Stock [Member]
Commitments and Contingencies [Line Items]
Common stock, shares issued | shares					71,430
Chief Executive Officer [Member] | Maximum [Member]
Commitments and Contingencies [Line Items]
Increase In Base Salary				$ 300,000
Chief Scientific Officer [Member]
Commitments and Contingencies [Line Items]
Employment Agreement Term
Common stock, shares issued | shares				35,715
Additional Common Stock Shares Issued | shares				35,715
Increase In Base Salary				$ 150,000
President [Member]
Commitments and Contingencies [Line Items]
Increase In Base Salary				275,000
President [Member] | Maximum [Member]
Commitments and Contingencies [Line Items]
Increase In Base Salary				$ 300,000
Vice President [Member]
Commitments and Contingencies [Line Items]
Employment Agreement Term
Common stock, shares issued | shares				35,715
Additional Common Stock Shares Issued | shares				35,715
Increase In Base Salary				$ 150,000
Vice President [Member] | Series A Convertible Preferred Stock [Member]
Commitments and Contingencies [Line Items]
Preferred stock, shares issued | shares				26,786
Additional Preferred Stock Shares Issued | shares				26,786
Chief Financial Officer [Member]
Commitments and Contingencies [Line Items]
Increase In Base Salary	$ 10,800	$ 9,000
Chief Financial Officer [Member] | Series A Convertible Preferred Stock [Member]
Commitments and Contingencies [Line Items]
Preferred stock, shares issued | shares		2,572

Subsequent Events (Details Text

Subsequent Events (Details Textual) - Jul. 21, 2015 - Subsequent Event [Member] - USD ($)	Total
Executive Vice President [Member]
Subsequent Event [Line Items]
Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance	225,000
Deferred Compensation Arrangement with Individual, Maximum Contractual Term	3 years
Executive Vice President [Member] | Year One [Member]
Subsequent Event [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense	$ 350,000
Executive Vice President [Member] | Year One [Member] | Deferred Bonus [Member]
Subsequent Event [Line Items]
Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount	75,000
Executive Vice President [Member] | Year Two [Member]
Subsequent Event [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense	375,000
Executive Vice President [Member] | Year Two [Member] | Deferred Bonus [Member]
Subsequent Event [Line Items]
Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount	75,000
Executive Vice President [Member] | Year Three [Member]
Subsequent Event [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense	400,000
Executive Vice President [Member] | Year Three [Member] | Deferred Bonus [Member]
Subsequent Event [Line Items]
Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount	$ 75,000
Chief Executive Officer [Member]
Subsequent Event [Line Items]
Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance	225,000
Deferred Compensation Arrangement with Individual, Maximum Contractual Term	3 years
Chief Executive Officer [Member] | Year One [Member]
Subsequent Event [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense	$ 350,000
Chief Executive Officer [Member] | Year One [Member] | Deferred Bonus [Member]
Subsequent Event [Line Items]
Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount	75,000
Chief Executive Officer [Member] | Year Two [Member]
Subsequent Event [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense	375,000
Chief Executive Officer [Member] | Year Two [Member] | Deferred Bonus [Member]
Subsequent Event [Line Items]
Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount	75,000
Chief Executive Officer [Member] | Year Three [Member]
Subsequent Event [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense	400,000
Chief Executive Officer [Member] | Year Three [Member] | Deferred Bonus [Member]
Subsequent Event [Line Items]
Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount	$ 75,000